Comparison of non-HDL cholesterol and waist circumference vs. triglyceride levels and waist circumference in predicting coronary heart disease risk by Joshi, Divya.
Comparison ofNon-HDL Cholesterol and Waist Circumference vs. Triglyceride Levels and 
Waist Circumference in Predicting Coronary Heart Disease Risk 
DivyaJoshi 
Submitted in Partial fulfillment 
Of the Requirements for the Degree of 
Masters of Science in Applied Health Sciences 
(Health Science) 
Supervisor: Dr. J. Liu 
The Faculty of Applied Health Sciences 
Brock University 
St. Catharines, ON 
Divya Joshi © January 2009 
ACKNOWLEDGEMENTS 
I would like to take this opportunity to thank all of the individuals that have contributed 
their time and support from beginning to end. 
Dr. Jian Liu - This thesis could not have been completed without your help, guidance and 
support. You have motivated me from the beginning to excel and accomplish my goals. 
You have given me an experience and an education for which I will always be thankful. 
Thank you for keeping your door open for me at any time and for the helpful advice 
throughout the completion of this thesis. 
Dr. Martin Tammemagi - Thank you for patiently guiding me through this process and 
never accepting less than my best efforts. Your availability and assistance throughout the 
competition of this thesis is greatly appreciated. 
Dr. Litsa Tsiani - Thank you for your insightful suggestions and opinions. 
Dr. Mike Plyley - Thank you for providing me with the opportunity to pursue the Masters 
degree. 
Mom, Dad, Gayatri, Harsha, Urvi, Jay, and Priyank - Thank you for your support and 
your belief that I could complete this chapter of my life. Your love and encouragement 
has motivated me to achieve my goals. 
Truth, Truth's mom, and all my friends - Thank you for your encouragement, love, 
support, and for always being there when I needed to talk. 
1 
ABSTRACT 
BACKGROUND: Dyslipidemia is recognized as a major cause of coronary heart disease 
(CHD). Emerged evidence suggests that the combination of triglycerides (TG) and waist 
circumference can be used to predict the risk of CHD. However, considering the known 
limitations of TG, non-high-density lipoprotein (non-HDL = Total cholesterol - HDL 
cholesterol) cholesterol and waist circumference model may be a better predictor of 
CHD. 
PURPOSE: The Framingham Offspring Study data were used to determine if combined 
non-HDL cholesterol and waist circumference is equivalent to or better than TG and 
waist circumference (hypertriglyceridemic waist phenotype) in predicting risk of CHD. 
METHODS: A total of3,196 individuals from Framingham Offspring Study, aged ~ 40 
years old, who fasted overnight for ~ 9 hours, and had no missing information on non-
HDL cholesterol, TG levels, and waist circumference measurements, were included in the 
analysis. Receiver Operator Characteristic Curve (ROC) Area Under the Curve (AUC) 
was used to compare the predictive ability of non-HDL cholesterol and waist 
circumference and TG and waist circumference. Cox proportional-hazards models were 
used to examine the association between the joint distributions of non-HDL cholesterol, 
waist circumference, and non-fatal CHD; TG, waist circumference, and non-fatal CHD; 
and the joint distribution of non-HDL cholesterol and TG by waist circumference strata, 
after adjusting for age, gender, smoking, alcohol consumption, diabetes, and hypertension 
status. 
RESULTS: The ROC AUC associated with non-HDL cholesterol and waist 
circumference and TG and waist circumference are 0.6428 (CI: 0.6183, 0.6673) and 
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0.6299 (CI: 0.6049, 0.6548) respectively. The difference in the ROC AVC is 1.29%. The 
p-value testing if the difference in the ROC AVCs between the two models is zero is 
0.10. There was a strong positive association between non-HDL cholesterol and the risk 
for non-fatal CHD within each TO levels than that for TO levels within each level of non-
HDL cholesterol, especially in individuals with high waist circumference status. 
CONCLUSION: The results suggest that the model including non-HDL cholesterol and 
waist circumference may be superior at predicting CHD compared to the model including 
TO and waist circumference. 
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CHAPTER 1. INTRODUCTION 
Coronary heart disease (CHD) is the single most common cause of death among 
middle-aged individuals around the world. In the U.S., it affects approximately 13 million 
people (Lofgren et aI., 2004). The risk of mortality and morbidity resulting from 
cardiovascular disease is of great public health concern. Therefore, it is important to 
identify the individuals in the population that are at increased risk of CHD. Many risk 
factors are associated with the increased risk of CHD, however much attention has been 
focused on the elevated lipid profile and its atherogenic properties as a very powerful risk 
factor for the cardiovascular disease (CVD). Elevated triglyceride (TG) levels, TG-rich 
very low density lipoprotein (VLDL) cholesterol, low density lipoprotein (LDL) 
cholesterol, and low levels of high-density lipoprotein (HDL) cholesterol are 
characteristic risk factors of CHD. Research from various studies suggests that 
dyslipidemia is a major cause of CVD. It is also known that lowering the lipid levels can 
slow the progression and reduce the risk of cardiovascular events (Brown et aI., 2000; 
Grundy, 2000). 
Nevertheless, recent research suggests that factors other than the traditional 
lipoproteins and lipids may be better predictors of CHD risk. In this regard, 
concentrations of apolipoprotein B (apo B), insulin resistance, and high level of small 
dense LDL cholesterol, which has been named the metabolic triad, was proposed as an 
important predictor of CHD risk (St-Pierre et aI., 2007). Metabolic triad is also highly 
prevalent among individuals with high accumulation of visceral adipose tissue (Lemieux 
et aI., 2000). However, there are increased costs associated with the measurement of 
insulin, apo B, and small dense LDL cholesterol, thereby limiting its use in clinical 
1 
practice. To overcome this limitation, waist circumference was suggested as a substitute 
for the measurement of visceral adipose tissue accumulation and fasting TG 
concentrations have been used to predict LDL size (St-Pierre et aI., 2002; Lemieux et aI., 
2000). Hypertriglyceridemic waist phenotype is defined as concurrently having plasma 
TG levels of ~177 mg/dL and waist circumference of ~90 cm in males (Lemieux et aI., 
2000), and TG levels of ~150 mg/dL and waist circumference of ~88 em in females 
(LeMonte et aI., 2003). However, the role of hypertriglyceridemia as an independent 
predictor for the risk of CHD is controversial. Various problems may arise as a result of 
using the hypertriglyceridemic waist phenotype to predict CHD risk. For example, it is 
difficult to determine if hypertriglyceridemia can independently predict the risk of CHD 
because of its association with abnormal lipid metabolism as well as other CHD risk 
factors (McBride, 2007; Ginsberg, 2002). Further, it is known that TG does not directly 
participate in the process of atherosclerosis but it exerts its effects indirectly through the 
accumulation of cholesterol-rich VLDL remnants in the extracellular matrix (Packard et 
aI., 2004). In addition, elevated TG levels indirectly affect the formation of atherosclerotic 
plaque by causing structural abnormalities in LDL and HDL particles. It causes the 
formation of small dense LDL cholesterol and reduces the size and quantity of HDL 
cholesterol thereby reducing its protective effects (Packard et aI., 2004). Therefore, a 
measurement of atherogenic lipoproteins, that include all the potential atherogenic 
lipoproteins such as LDL, IDL, VLDL and its remnants, and is a simple and an 
inexpensive measure, may be a better clinical tool. 
Research indicates that elevated TG-rich lipoproteins such as VLDL may be an 
independent risk factor for CHD. As a result, the possible measure is the non-high density 
lipoprotein (non-HDL) cholesterol, which combines all atherogenic lipoproteins into a 
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single fraction, making the use of non-HDL cholesterol a simple and relatively 
inexpensive indicator of CHD risk. It is calculated by subtracting the HDL cholesterol 
from total cholesterol. Non-HDL cholesterol incorporates LDL, IDL, and VLDL 
cholesterol, and it reflects the cholesterol content of all apo B containing lipoproteins. 
Non-HDL cholesterol can be used as a predictor of CHD in individuals with and without 
high TG levels, type 2 diabetes, and metabolic syndrome (Hoenig, 2008; Liu et aI., 2006; 
Packard et aI., 2004; Lehto et aI., 1997). There is less day-to-day variability in non-HDL 
cholesterol compared to TG concentrations and is unaffected by TG levels. Unlike TG, 
non-HDL cholesterol requires measurements of only total cholesterol and HDL 
cholesterol which can be measured reasonably accurately in the non-fasting state and it is 
readily derived from the routine lipoprotein profile. For these reasons non-HDL 
cholesterol may be a highly useful lipid measure for predicting the risk of CHD and 
evaluating response in treatment of hyperlipidemia. 
Obesity is another risk factor for CHD. In 2002, worldwide there were more than 
one billion adults categorized as overweight (BMI ~ 25.0 kg/m2) and 300 million as obese 
(BMI ~ 30.0 kg/m2) (Haffner, 2006). Increased abdominal adiposity is clearly associated 
with increased risk for CVD and premature death (Smith et aI., 2005). Various studies 
have indicated that high waist circumference is associated with increased rates of 
cardiovascular and metabolic risk factors and an increased risk of chronic diseases, 
including diabetes, hypertension, and CHD (Smith et aI., 2005). Therefore, combining 
non-HDL and waist circumference may prove to be a better indicator of CHD risk 
compared to hypertriglyceridemic waist phenotype. Unfortunately, there is lack of 
information with respect to the combination of non-HDL cholesterol and waist 
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circumference and its association with risk of CHD compared to hypertriglyceridemic 
waist phenotype. 
The purpose of this study is to compare using non-HDL cholesterol and waist 
circumference, versus using TG and waist circumference in predicting the risk of non-
fatal CHD. 
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CHAPTER 2. LITERATURE REVIEW 
2.1 Introduction 
Research from experimental animals, observational studies, and clinical trials 
indicate that dyslipidemia and abdominal obesity are two major independent risk factors 
of CHD (Carr et aI., 2004; Paccaud et aI., 2000; Zhou et aI., 2000). LDL cholesterol has 
been used for a long time in management of dyslipidemia (Gotto, 1993). 
Although, hypertriglyceridemic waist phenotype has been proposed to predict the 
risk of CHD, several concerns regarding using TG in this method are raised. In particular, 
the requirement of overnight fasting and larger intra-individual variation may limit its 
application in clinical practice. 
This chapter will review both lipid risk factors and non-lipid risk factors in the 
process of atherosclerosis, and explore the rational of using non-HDL cholesterol and 
waist circumference in detecting the risk ofCHD. 
2.2 Structure, Function, and Classification of Lipids and Lipoproteins 
The components of lipids include fatty acids, TG, cholesterol, and lipoproteins. 
Lipids serve several important physiologic functions within the human body. Lipids are 
an important source of energy and are essential component of the cell structure. For cell 
membranes, cholesterol provides an essential stabilizing function and facilitates 
membrane transport. It is required for biosynthesis of hormones and is a precursor of 
adrenal and sex hormones. Cholesterol is also required for the synthesis of bile acids; bile 
acids are crucial for the absorption of dietary fat in the small intestine. TG offers an ideal 
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means of energy storage and production. Through lipolysis, the cardiac and skeletal 
muscle cells extract and convert the TG from circulating lipoproteins to fatty acids and 
glycerol. Fatty acids are a major energy source for muscle cells. In a number of cells, such 
as muscle and liver cells, fatty acids can also be converted to glucose through 
gluconeogenesis (Kingsbury et aI., 2003). 
Although lipids serve several important functions within the body, they are 
hydrophobic and cannot be transported directly in the blood. Therefore, they bind to 
specific proteins called apolipoproteins to form soluble lipid-protein complexes called 
lipoproteins (Jain et aI., 2007). Plasma lipoproteins are composed of TG and cholesterol 
esters at the core making the core hydrophobic, and phospholipids and apolipoproteins 
form the outer polar layer (Kingsbury et aI., 2003). Thus, the amphipathic properties of 
apolipoproteins make the lipids soluble in an aqueous environment and thereby act as an 
interface between plasma and the core components. It is in this form that the major lipids 
circulate in the plasma. Several lipoprotein complexes exist and they are identified based 
on their size, density, and lipid and apolipoprotein composition as seen in Figure 1. 
(Homma, 2006; Sawle et aI., 2002). There are five main types of lipoproteins present in 
the plasma including chylomicrons, very low-density lipoprotein (VLDL) (pre-p-
lipoproteins), intermediate density lipoprotein (IDL), low density lipoprotein (LDL) (P-
lipoprotein), and high density lipoprotein (HDL) (a-lipoprotein) cholesterol (Lewis, 
1973). Generally, in clinical practice, LDL and IDL are combined into a single fraction 
termed LDL cholesterol. According to size, LDL and HDL are small particles, VLDLs are 
medium sized particles, and chylomicrons are large particles (Lewis, 1973). These 
lipoproteins contain TG, cholesterol esters, and phospholipids in different proportions. 
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LDL contains cholesterol as its major lipid, while VLDL and chylomicrons contain TG as 
their major lipid component (Lewis, 1973). 
2.3 Basic Description of Lipids and Lipoproteins 
2.3.1 LDL Cholesterol 
LDL cholesterol makes up 60 to 70% of the total serum cholesterol. It contains a 
single apolipoprotein called apo B-lOO (apo B). LDL is the major atherogenic lipoprotein 
and has been identified as the primary target of cholesterol lowering therapy by the 
National Cholesterol Education Program - Adult Treatment Panel III (NCEP ATP III, 
2002). 
2.3.2 HDL Cholesterol 
HDL cholesterol normally makes up 20 to 30% of the total serum cholesterol. The 
major apolipoproteins of HDL cholesterol are apo A-I and apo A-II (NCEP ATP III, 
2002). HDL cholesterol levels are inversely associated with CHD risk. Some evidence 
shows that HDL cholesterol protects against the development of atherosclerosis, although 
low levels ofHDL cholesterol reflects the presence of other atherogenic factors. 
2.3.3 VLDL Cholesterol 
The VLDL cholesterol contains TG-rich lipoproteins, but contains only 10 to 15% 
of the total serum cholesterol. The major apolipoproteins ofVLDL are apo B-I00, apo C-
I, apo C-II, apo C-III, and apo E (NCEP ATP III, 2002). VLDL are precursors of LDL 
cholesterol and are produced by the liver. VLDL remnants, a form of VLDL is known to 
be atherogenic. VLDL remnants are partially degraded VLDL and are rich in cholesterol 
ester. 
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2.3.4 Chylomicrons 
Similar to VLDL, chylomicrons are also TG-rich lipoproteins. They are formed in 
the epithelium of the small intestine from dietary fat. They contain the same lipoproteins 
as VLDL except that apo B-48 is present instead of apo B-100 (NCEP ATP III, 2002). 
Partially degraded chylomicrons known as chylomicron remnants are also atherogenic. 
Although LDL is the primary target for lipid lowering therapy, growing evidence 
indicates that VLDL plays important roles in the process of atherosclerosis. 
2.4 Pathways of Lipid Transport 
There are three pathways involved in the generation and transport of lipids. These 
include the exogenous pathway, the endogenous pathway, and the reverse cholesterol 
transport pathway. The exogenous pathway is the pathway of dietary lipid transport from 
intestine to the liver (Figure 2). After digestion and absorption of dietary fat, 
chylomicrons, composed of TG, cholesterol, and apolipoproteins, are formed in the 
epithelial cells of the intestines (Jain et aI., 2007). In the bloodstream, chylomicrons 
collect lipids and transport dietary TG from the intestines to adipose tissues and muscles 
for storage. Dietary cholesterol is then transported to the liver. On the endothelial cells of 
the adipose tissue and muscles, the TGs undergo hydrolysis via the action of the enzyme 
lipoprotein lipase and fatty acids are released (Jain et aI., 2007). Some of the components 
of the chylomicrons are repackaged into other lipoproteins, for example, some 
apolipoproteins are transferred to HDL, and the remaining chylomicron remnant particles 
are taken up by the liver via LDL receptors (Jain et aI., 2007). This results in dietary TG 
storage in adipose tissue and muscles. 
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The endogenous pathway is the route for synthesizing and transporting 
lipoproteins from the liver to the target cells (Figure 2). TG and cholesterol from the liver 
are packaged and then released in the circulation as VLDL particles. VLDL is transported 
to adipose tissue and muscles where lipoprotein lipase hydrolyzes it and fatty acids and 
glycerol are released (Jain et aI., 2007). The fatty acids are taken up by muscle cells and 
adipose tissue for production of energy and storage respectively. After the hydrolysis of 
VLDL, it becomes a VLDL remnant. Most of the VLDL remnants are taken up by the 
liver by means of LDL receptors and the remaining remnant particles become IDL (Jain et 
aI., 2007). Some of the IDL particles are reabsorbed by the liver via the LDL receptors 
while the others circulate until they hydrolyzed in the liver by hepatic-triglyceride lipa$e 
to form LDL (Jain et aI., 2007). At each hydrolysis step TG are lost to the adipose tissue 
and muscles resulting in LDL particles rich in cholesterol. This results in the transfer of 
TG from liver to target cells via LDL. LDL is the main carrier of circulating cholesterol in 
the body because it transports cholesterol from the plasma and delivers it to the peripheral 
tissues. LDL represents the final stage in the catabolism ofVLDL. Most LDL particles are 
removed from the plasma through LDL receptors in the liver while the remaining LDL is 
removed by the scavenger pathways in the cells (Jain et aI., 2007). As LDL is taken up by 
receptors, free cholesterol is released and accumulated within the cells. The uptake of 
LDL by the LDL receptors regulates the LDL concentrations in the blood via several 
mechanisms including decreasing the synthesis ofhydroxyl-3-methylglutaryl coenzyme A 
reductase (which controls the rate of cholesterol synthesis), suppressing the synthesis of 
new LDL receptors in the cells, and activating acyl-coenzyme A cholesterol 
acyltransferase (which esterifies free cholesterol into cholesterol ester, storing cholesterol 
in the cell) (Jain et aI., 2007). 
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Finally, the third pathway is the reverse cholesterol pathway. Reverse cholesterol 
transport is a pathway where cholesterol is transported from the tissues and returned to the 
liver to be excreted into the feces via bile. HDL is involved in the reverse cholesterol 
transport and the transfer of cholesteryl esters between lipoproteins. HDL is fonned 
through a maturation process in which precursor particles secreted by the liver and the 
intestine go through a series of conversions to attract cholesterol from cell membranes and 
free cholesterol to the core ofthe HDL particle (Asztalos et aI., 2003). As the cell dies and 
the cell membranes turnover, free cholesterol is released into the plasma. It is immediately 
absorbed into HDL particles, esterified with a long chain fatty acid by lecithin cholesterol 
acyl transferase, and transferred to VLDL or IDL by a cholesteryl ester transfer protein in 
plasma (Asztalos et aI., 2003). Eventually, it is taken up by the liver as IDL or LDL, thus 
resulting in the recovery of cholesterol from cell membranes, which is then reincorporated 
into LDL or returned to the liver (Jain et aI., 2007; Asztalos et aI., 2003). 
Abnonnalities in these pathways may result in hyperlipoproteinemias. High TG 
and low HDL cholesterol levels are components of the metabolic syndrome which is 
discussed below in further detail. 
2.5 LDL Cholesterol as the Primary Target of Therapy 
LDL cholesterol is identified as the primary target for cholesterol lowering therapy 
in the NCEP ATP I (1988), ATP II (1994), and ATP III (2002). Evidence from animal, 
pathological, clinical, genetic, and different types of population studies has shown that 
LDL is the most abundant atherogenic lipoprotein. The role of LDL in causing CHD has 
been supported by controlled clinical trials. LDL cholesterol levels as low as 25 to 60 
mg/dL is physiologically sufficient (Brown et aI., 1986). Animal species that do not 
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develop atherosclerosis nonnally have LDL cholesterol concentrations below 80 mgldL 
(NCEP ATP III, 2002). In contrast, high levels of LDL cholesterol are known to be 
atherogenic. For instance, the Framingham Heart Study (Wilson et aI., 1998), and the 
Lipid Research Clinics trial (1984), found a direct association between LDL 
concentrations and the rate of CHD in males and females who were initially free of CHD. 
There is also a direct relationship between LDL cholesterol levels and recurring coronary 
events in individuals with pre-existing CHD (Rossouw et aI., 1990; Pekkanen et aI., 1990; 
Wong et aI., 1991). Studies perfonned on different populations also show that those with 
higher levels oftotal or LDL cholesterol have higher rate of atherosclerosis and CHD than 
those who have lower levels (Keys et aI., 1984a). People migrating from regions where 
cholesterol levels are low to regions with high cholesterol levels show an increase in their 
cholesterol levels as well as the risk for developing CHD (Kagan et aI., 1974). Increased 
cholesterol levels in adolescents are also associated with development of CHD later in life 
(Stamler at aI., 2000). In addition, elevated LDL causes CHD in individuals with genetic 
fonns of hypercholesterolemia (Brown et aI., 1986). In these individuals, atherosclerosis 
and CHD is known to occur even in the complete absence of other risk factors, thus 
providing strong evidence that LDL is a powerful atherogenic lipoprotein. 
Even though high LDL cholesterol levels are associated with increased CHD risk 
and is considered as the primary target of therapy, estimation of LDL cholesterol has 
significant limitations, especially in individuals with high TG levels and those with 
diabetes mellitus. The limitations are due to the abnonnal composition of TG-rich 
lipoproteins found in individuals with high TG levels, which are not considered in the 
Friedewald fonnula (Aguilar-Salinas et aI., 2002). Non-HDL cholesterol may overcome 
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the limitations of LDL cholesterol. The cut-offs for LDL cholesterol levels are presented 
in Table 1. 
2.6 Low HDL Cholesterol as an Independent Risk Factor for CHD 
Epidemiological .studies show low HDL cholesterol levels to be an independent 
risk factor for CHD even after controlling for other risk factors. In animal models, high 
levels of HDL levels have shown to have protective effect against atherosclerosis 
(Tangirala et aI., 1999). Conversely, individuals with high HDL cholesterol levels have 
low CHD risk. Various studies show that the antioxidant and anti-inflammatory properties 
ofHDL also inhibit atherosclerosis (Navab et aI., 2000; van Lenten et aI., 1995). Also, the 
Framingham Heart Study showed that high HDL cholesterol levels are associated with 
reduced risk for CHD. According to the NCEP ATP III report (2002), presence of high 
HDL cholesterol indicated a removal of one risk factor from the risk factor count used for 
setting treatment goals for LDL cholesterol. The cut-offs for HDL cholesterol levels are 
presented in Table 2. 
2.7 Non-Lipid Risk Factors 
A number of non-lipid risk factors are associated with increased CHD risk and 
must be considered in preventive efforts. Some of these risk factors are modifiable while 
others are non-modifiable and therefore their presence will require for more intensive 
lowering ofLDL cholesterol. 
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2.7.1 Modifiable Risk Factors 
The first goal for people with modifiable non-lipid risk factors is to alter them to 
reduce CHD risk. There are several modifiable risk factors that are associated with CHD 
risk. 
2.7.1.1 Hypertension 
The Sixth Report of the Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure (1997) defines hypertension as a 
systolic blood pressure 2:140 mmHg or diastolic blood pressure of 2:90 mmHg or current 
use of antihypertensive medication. Epidemiological studies have shown that high blood 
pressure is associated with increased risk of CHD (van den Hoogen et aI., 2000; Franklin 
et aI., 1999; Staessen et aI., 1997). Further, blood pressure reduction in individuals with 
hypertension reduces the risk of CHD (NCEP ATP III, 2002). In individuals with 
elevated blood pressure, intensive LDL lowering therapy is required (NCEP ATP III, 
2002). 
2.7.1.2 Cigarette Smoking 
Cigarette smoking is associated with increased risk ofCHD (Pyorala at aI., 1994). 
There is dose dependent relationship between smoking and CHD risk (NCEP ATP III, 
2002). There is substantial reduction in CHD risk in those people who quit smoking. It is 
suggested that smoking reduces the risk of in CVD within months after quitting. NCEP 
ATP III (2002) recommends that prevention of smoking and smoking cessation should 
receive emphasis in order to reduce CHD risk. 
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2.7.1.3 Diabetes 
Diabetes, defined as having fasting blood glucose of 126 mg/dL or greater (Gavin 
et aI., 1998). Both type 1 and type 2 diabetes mellitus increases the risk of CHD. The 
NCEP ATP III (2002) has listed type 2 diabetes as a CHD risk equivalent, meaning 
persons with type 2 diabetes have a 10-year risk for major coronary events (myocardial 
infarction and CHD death) equivalent to the risk in CHD patients without diabetes. The 
mortality rates in diabetic individuals having CHD are higher than in non-diabetic 
individuals (Miettinen et aI., 1998). The increase in CHD risk due to high blood glucose 
levels is independent of dyslipidemia and obesity status (NCEP ATP III, 2002). However, 
management of other risk factors is suggested to help reduce the incidence of CHD in 
individuals with diabetes. For instance, according to the UK Prospective Diabetes Study 
Group (1998) controlling high blood pressure in those with diabetes will help lower the 
risk of CHD. Therefore, presence of diabetes should lead to modification of treatment 
goals for LDL cholesterol. 
2.7.1.4 Metabolic Syndrome 
The metabolic syndrome is strongly associated with insulin resistance. Along with 
insulin resistance, the NCEP ATP III (2002) has considered high TG levels, low HDL 
cholesterol, abdominal obesity, and high blood pressure in their definition of metabolic 
syndrome. The criteria for clinical identification of metabolic syndrome are presented in 
Table 3. Individuals having three of the five risk factors are qualified as having metabolic 
syndrome (Cook et aI., 2003). The clustering of these risk factors is associated with an 
increased risk for CVD compared to the risk associated with each condition considered 
separately. Metabolic syndrome and its consequences present a challenge to the healthcare 
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system, particularly due to the dramatic increase in the prevalence of obesity and type 2 
diabetes mellitus. Insulin resistance and obesity are generally considered two important 
underlying risk factors for metabolic syndrome (Esmaillzadeh et aI., 2006; St-Onge et aI., 
2004). Insulin resistance may be caused by abdominal obesity and physical inactivity, and 
it is known to be associated with increased blood pressure (Copper-DeHoff et aI., 2007). 
2.7.1.5 Overweight/Obesity 
Overweight is defined as having a BMI between 25.0 to 29.9 kg/m2 and obesity is 
defined as a BMI of 2:30.0 kg/m2 and (NCEP ATP III, 2002). Although some people, 
especially athletes, classified as overweight have increased muscle mass, most people 
have excess body fat. Overweight and obese people also have the presence of other CHD 
risk factors including high LDL cholesterol, low HDL cholesterol, high VLDL, high TG, 
type 2 diabetes, and hypertension. Overweight and obesity are associated with increase in 
the risk ofCHD, stroke, and all-cause mortality (Calle et aI., 1999; Manson et aI., 1990). 
CHD risk is particularly higher in individuals who are abdominally obese, defined by a 
waist circumference greater than 102 cm in males and 88 cm in females. According to the 
NCEP ATP III report (2002), obesity is considered a direct target for clinical intervention 
instead of an indicator for modification of LDL treatment because the risk associated with 
overweight and obesity may be due to the presence of other major CHD risk factors. 
2.7.1.6 Physical Inactivity 
Physical inactivity is associated with increased risk for CHD. In contrast, physical 
activity is known to lower LDL cholesterol and TG levels, raise HDL cholesterol, 
improve insulin sensitivity, and lowers blood pressure in those with hypertension. 
Physical activity has been shown to reduce the risk of CHD. Therefore, physical inactivity 
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is considered to be one of the major modifiable risk factor for CHD (NCEP ATP III, 
2002). One possible explanation for the increase in CHD risk may be that physical 
inactivity reduces energy expenditure and is associated with obesity and CHD risk factors 
(Grundyet aI., 1999). Physical activity should be one of the important targets for lifestyle 
changes. 
2.7.1.7 Atherogenic Diet 
Diets high in saturated fatty acids and cholesterol increases the risk of CHD by 
raising LDL cholesterol levels. High sodium intake is also associated with hypertension. 
In contrast, individuals consuming diets high in fruits, vegetables, whole grains, and 
unsaturated fatty acids appear to have low risk of CHD due to the presence of 
antioxidants, folic acid, B-vitamins, omega-3 fatty acids, and other nutrients (Krauss et 
aI.,2000). 
2.7.2 Non-Modifiable Risk Factors 
Several risk factors cannot be modified, their presence indicate the need for a more 
intensive LDL lowering therapy. 
2.7.2.1 Age 
The risk for CHD increases steeply with increasing age in both males and females. 
Compared to younger individuals, the risk for CHD is higher in older people for any given 
level ofLDL cholesterol (Wilson et aI., 1998). The main reason that the risk ofCHD rises 
with age is that there is a continuous accumulation of atherosclerotic plaques with 
increasing age. Plaque ruptures produce acute coronary events such as unstable angina or 
myocardial infarction, or in cases where plaques grow large, coronary obstruction can 
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occur (NCEP ATP III, 2002). Development of atherosclerosis also reflects the presence of 
other CHD risk factors. Older people are exposed to the risk factors for a longer period of 
time compared to the younger people. The NCEP ATP III (2002) has suggested that age 
2:45 years in males and 2:55 years in females is a positive risk factor for CHD. 
2.7.2.2 Male Sex 
At any given age males are at higher risk for CHD compared to females (Wilson et 
aI., 1998). According to the NCEP ATP III (2002), risk in females is approximately 10 to 
15 years behind that of males. The reasons for difference in CHD risk between males and 
females are not fully understood. One explanation may be that risk factors such as high 
LDL cholesterol, high blood pressure, and low HDL cholesterol are present at an earlier 
age in males than in females (NCEP ATP III, 2002). However, males and females have 
similar response to LDL lowering drug treatments (NCEP ATP III, 2002). 
2.7.2.3 Family History of Premature CHD 
CHD tends to cluster in families. The family history of premature CHD is positive 
if CHD or sudden death is reported in first degree male relatives younger than 55 years 
old and first degree female relatives younger than 65 years of age (NCEP ATP III, 2002). 
The first degree relative may be a parent, sibling, or offspring. Results from many 
prospective studies show that a family history of premature CHD is an independent risk 
factor even after adjusting for other risk factors. The risk of CHD increases with the 
number of first degree relatives affected and the age of onset of CHD (Pohjola-Sintonen et 
aI., 1998). The siblings of the affected individual have the highest risk of CHD, may be 
due to common cultures, environments, exposures, and genetics. 
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2.8 Hypertriglyceridemic Waist Phenotype 
Recent studies have indicated that the process of atherosclerosis is linked to 
components of the metabolic syndrome. The increase in the prevalence of obesity and 
type 2 diabetes is resulting in an increase in the incidence rates of CHD. There is 
increasing evidence that factors other than the traditional lipoprotein-lipid profile may 
further help in the identification of individuals at high risk for CHD. In this regard, The 
Quebec Cardiovascular Study found that hyperinsulinemia, increased levels of plasma apo 
B, and small dense LDL cholesterol are characteristics of insulin resistance and 
abdominal obesity and are known to predict increased risk of CHD (Senechal et al., 2005; 
St-Pierre et aI., 2002; Lamarche et aI., 1998). Hyperinsulinemia, increased levels of 
plasma apo B, and small dense LDL cholesterol are collectively known as the atherogenic 
metabolic triad. It is also known that the atherogenic metabolic triad is commonly found 
among abdominally obese individuals, especially those having increase amounts of 
visceral adipose tissue (St-Pierre et aI., 2002; Despres et aI., 2000). Obesity is also a risk 
factor for type 2 diabetes mellitus. Abdominal obesity is associated with changes in 
carbohydrate and lipid metabolism as well as with the inflammation resulting from 
atherosclerosis that contributes to increased CHD risk (St-Pierre et aI., 2002). These 
studies indicate that atherogenic metabolic triad features and abdominal obesity 
measurements may predict the risk of CHD. However, there are increased costs associated 
with measurement of visceral adipose tissue accumulation and with the measurement of 
insulin, apo B, and LDL particle size thereby limiting its use in clinical practice. To 
overcome this limitation, waist circumference is used as a substitute for the measurement 
of visceral adipose tissue accumulation and fasting TG concentrations have been used to 
predict LDL size (St-Pierre et aI., 2002; Lemieux et aI., 2000). This is illustrated in Figure 
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3. Rypertriglyceridemic waist phenotype defined as concurrently having plasma TG 
levels of2:177 mg/dL and waist circumference of2:90 cm in males (Lemieux et aI., 2000), 
and TG levels of2:150 mg/dL and waist circumference of2:88 cm in females (LeMonte et 
aI., 2003) may be a simple predictor of atherogenic metabolic triad features and CRD risk. 
The cut-offs for TG concentrations are shown in Table 4. According to the NCEP 
ATP III (2002), a normal TG level is defined as <150 mg/dL and hypertriglyceridemia is 
defined as TG concentrations of 2:150 mg/dL. The role of hypertriglyceridemia as an 
independent predictor for the risk of CRD is controversial. Various studies have shown a 
strong association between hypertriglyceridemia and an increase in CRD risk (Bansal et 
aI., 2007; Eberlyet aI., 2003; Abdel-Maksoud, 2002). It has repeatedly been found that 
many patients with CRD have elevated TG, small dense LDL cholesterol, and decreased 
levels of RDL cholesterol, which are characteristic of the atherogenic lipoprotein profile 
found in patients with metabolic syndrome and diabetes mellitus. A large meta-analysis of 
population-based prospective studies also indicated that hypertriglyceridemia is a 
predictor of CRD even after adjusting for other risk factors such as low RDL levels 
(Austin et al., 1998). Thus, there is strong evidence indicating that hypertriglyceridemia is 
a risk factor for CRD, but it is difficult to determine the strength of its contribution to 
CRD risk because it is known to be associated with abnormal lipid metabolism and other 
CRD risk factors such as obesity, insulin resistance, diabetes mellitus, hypertension, high 
LDL cholesterol, and low levels of RDL cholesterol (McBride, 2007; Ginsberg, 2002). 
Therefore one would conclude that individuals with hypertriglyceridemia are at increased 
risk for CRD, even when this increased risk cannot be explained by hypertriglyceridemia 
itself. Meta-analyses that support the independent association of elevated TG and CRD 
emphasizes the atherogenicity of TG-rich lipoproteins. The TG-rich lipoproteins include 
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the remnant particles of VLDL and IDL cholesterol. These remnant lipoproteins have 
many properties that are similar to the properties of LDL. In the bloodstream, most of the 
TG is carried by VLDL in the fasting state and chylomicrons in the fed state (Packard et 
aI., 2004). Therefore, measurement of TG in the fasting state reflects VLDL 
concentrations. However, in conditions where TG levels are elevated to ~500 mg/dL, 
chylomicrons are present in the circulation for a long period of time thereby contributing 
to the fasting plasma TG concentrations (Packard et aI., 2004). Whether the chylomicrons 
themselves have atherogenic properties is still not known. 
Further, it is also suggested that unlike cholesterol, TG itself is not deposited in the 
atherosclerotic plaques. Instead, the effect of TG on the formation of atherosclerotic 
plaques can be explained by the accumulation of cholesterol-rich VLDL remnants and the 
structural abnormalities in LDL and HDL particles caused by hypertriglyceridemia 
(Packard et aI., 2004). At TG levels of approximately 200 to 500 mg/dL, most cholesterol 
occurring in VLDL cholesterol is contained in the small remnant VLDL particles that are 
then converted to IDL cholesterol (Bjorkegren et aI., 2000). Generally, each remnant 
particle contains more cholesterol than an LDL particle (Packard et aI., 2004). Recent 
studies have shown that elevated VLDL particles are atherogenic and are associated with 
increased CHD risk (Liu et aI., 2006). Remnant lipoproteins cause the buildup of 
cholesteryl esters in macrophages in the arterial walls, promoting the formation of foam 
cells and forming the atherosclerotic lesions (Packard et aI., 2004; Tanaka, 2004). 
Further, remnant particles have also been shown to promote platelet aggregation 
(Saniabadi et aI., 1997), impair endothelial function (Kugiyama et aI., 1998), promote 
adhesion of monocytes to endothelial cells (Kawakami et aI., 2002), and promote 
proliferation of vascular smooth muscle cells (Kawakami et aI., 2003). In experimental 
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animals, cholesterol-rich remnants have been known to cause atherosclerosis (Breslow, 
1996). In clinical trials elevated levels of remnants were found to be strong predictors of 
coronary atherosclerosis or CHD (Karpe et aI., 2001; Takeichi et aI., 1999). 
As mentioned earlier, the effects of TO on the process of atherosclerosis can also 
be explained by the abnormalities in the metabolism of HDL and LDL particles. 
Hypertriglyceridemia affects the metabolism of LDL and HDL particles by increasing the 
atherogenic properties of LDL and the reducing the cardioprotective effects of HDL. 
When TO levels are increased to >150 mg/dL, the large TO-rich VLDL levels are also 
elevated which enhances the action of cholesteryl ester transfer proteins (Packard et aI., 
2004). Therefore the cholesteryl ester transfer protein activity is regulated by TO 
concentrations. TO is transferred from VLDL into LDL and HDL, and cholesteryl esters 
are transferred from LDL and HDL into VLDL to promote remnant formation. As a result 
of lipid exchange, HDL is converted to TO-rich HDL and the normal size cholesteryl 
ester-containing LDL (LDL I and LDL II) are converted into TO-rich LDL particles 
(Packard et aI., 2004). The TO-rich LDL can be hydrolyzed, via the action of hepatic 
lipase, into small, dense LDL. Small, dense LDL is a type of LDL considered to be more 
atherogenic than normal size LDL because it has decreased binding capacity to the LDL 
receptors, leading to an increase in the time spent in the plasma (Woods et aI., 2006). It is 
also more readily oxidized than larger LDL particles and is more likely to be incorporated 
into the extracellular matrix during plaque formation and therefore is considered to be 
highly atherogenic (Packard et aI, 2004). 
Similarly, elevated plasma TO concentrations also affect HDL levels .. The inverse 
association ofHDL with TO is important since TO plays a crucial role in the regulation of 
HDL metabolism. TO plays a role in regulating the type, size, and quantity of HDL 
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particles. In the blood vessels, cholesteryl ester transfer proteins assist in the exchange of 
lipids and apolipoproteins between TG-rich lipoproteins and HDL cholesterol (Woods et 
aI., 2006). Thus, elevated TG leads to the production ofTG-rich HDL particles, which are 
hydrolysed by hepatic lipase. This hydrolysis results in the fonnation of small HDL 
particles which are more rapidly cleared from the blood than larger particles (Woods et 
aI., 2006). Since they are more rapidly cleared from the blood, the concentrations of HDL 
are decreased and therefore its availability for transporting cholesterol from arterial walls 
back to the liver is also diminished (Yang et aI., 2005). Nonnally, HDL promotes reverse 
cholesterol transfer, inhibits the fonnation of atherosclerotic plaques, and stabilizes 
lesions. However, when TG levels are elevated, the size and quantity ofHDL particles are 
decreased thereby reducing these cardioprotective effects of the HDL cholesterol. The 
resulting lipid profile consisting of elevated TG, low HDL, and increase levels of small, 
dense LDL, is known as the atherogenic lipoprotein phenotype or the lipid triad, and is 
typically found in individuals with metabolic syndrome and type 2 diabetes, both of which 
are associated with increased CHD risk (Vinik, 2005). 
In summary, even though it is suggested that hypertriglyceridemia is a risk factor 
for CHD, it is difficult to detennine if it can independently predict the risk of CHD 
because of its association with abnonnal lipid metabolism as well as other CHD risk 
factors. Further, it is clear that TG does not directly participate in the process of 
atherosclerosis but it exerts its effects indirectly through the accumulation of cholesterol-
rich VLDL remnants in the extracellular matrix. Also, elevated TG levels cause the 
fonnation of small dense LDL cholesterol and reduce the size and quantity of HDL 
cholesterol thereby reducing the cardioprotective effects ofHDL cholesterol. 
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2.9 Non-HDL Cholesterol 
Although there are several assays available for identification and measurement of 
remnant lipoproteins including the ultracentrifugation, electrophoresis, and 
immunological techniques, they are not recommended for clinical practice (NCEP ATP 
III, 2002). Therefore, elevated VLDL cholesterol is used to indicate elevated atherogenic 
remnants in individuals with TG levels ~200 mg/dL. Since VLDL cholesterol is highly 
correlated with atherogenic remnant lipoproteins, it can be combined with LDL 
cholesterol to provide a better estimation of the risk of CHD in individuals with elevated 
TG concentrations. VLDL, IDL, and LDL cholesterol together are known as non-HDL 
cholesterol. Non-HDL cholesterol levels are available from the standard lipid profile and 
can be determined by subtracting HDL cholesterol from the total cholesterol. Non-HDL 
cholesterol provides information on the concentrations of all atherogenic lipoproteins 
including the LDL, VLDL, IDL, and lipoprotein (a). Non-HDL cholesterol is highly 
correlated with total apo B concentration which is the major apolipoprotein of all 
atherogenic lipoproteins and is a strong predictor of atherosclerosis and CHD (Lemieux et 
aI., 2000; Larmarche et aI., 1996). 
In individuals with TG levels that are <200 mg/dL, elevation of both LDL and 
VLDL cholesterol are associated with increased risk of CHD (Liu et aI., 2006). However, 
when TG levels are elevated to ~200 mg/dL, VLDL levels increase, and LDL 
concentrations are less well correlated with non-HDL concentrations. As a result, LDL 
concentrations alone cannot identify the risk associated with atherogenic lipoproteins and 
non-HDL cholesterol is considered to be a better marker for the total atherogenic 
lipoprotein levels compared to LDL cholesterol alone (Liu et aI., 2006; Packard et aI., 
2004). 
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2.9.1 Predictive Value of Non-HDL Cholesterol 
Various studies have indicated the ability of non-HDL cholesterol to predict 
cardiovascular risk. A recent study assessed the association of TG concentrations, LDL, 
HDL, and non-HDL cholesterol, and found that after adjusting for age, gender, race, 
cigarette smoking, hypertension, obesity, family history of premature CHD, and 
increasing quartiles of lipid levels, only the association of non-HDL cholesterol with 
coronary artery calcium scores remained statistically significant (p = 0.002) (Orakzai et 
aI., 2009). In a 24-year follow-up study done on Finnish males aged 30 to 61 years 
showed that non-HDL cholesterol was a significant predictor of CHD death (Keys et aI., 
1984b). Similar results were obtained in a 10 year follow-up of Italian males aged 45 to 
65 years (Menotti et aI., 1992). Another prospective study done on Finnish patients with 
type 2 diabetes aged 45 to 64 years showed that there was a twofold increase in the risk of 
CHD mortality or morbidity independent of other cardiovascular risk factors (Lehto et aI., 
1997). In the Lipid Research Clinics Program Follow-up Study, during the 19-year 
follow-up period, cardiovascular death occurred in 234 of 2,406 males and 113 of 2,056 
females aged 40 to 64 years without cardiovascular disease at study entry (Cui et aI., 
2001). Compared to males with non-HDL cholesterol levels of < 160 mgldL, males with 
160 to 190 mgldL, 190 to 220 mgldL, and ~ 220 mgldL had increased risk of 
cardiovascular mortality by 14%, 43% and 114% respectively. Similarly, females with 
non-HDL levels of 160 to <190 mgldL, 190 to 220 mgldL, and ~ 220 mgldL had 
increased risk of cardiovascular mortality by 47%, 61% and 143% respectively. In this 
study, compared to total cholesterol and LDL cholesterol, non-HDL cholesterol was the 
strongest predictor of cardiovascular mortality in both genders. Another prospective 
study, the Bypass Angioplasty Revascularization Investigation trial showed that non-HDL 
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cholesterol level was a strong and independent predictor of outcomes among 1,514 elderly 
patients diagnosed with coronary artery disease (Bittner et aI., 2002). Multivariate 
analyses with a large number of covariates showed that non-HDL cholesterol was the 
strongest predictor of myocardial infarction and the only predictor of angina with a 4.9% 
increase in risk for every 10 mg/dL increase in non-HDL concentrations. Triglyceride 
levels were only associated with a 1.6% increase in risk of myocardial infarction. Non-
HDL cholesterol was independently associated with the risk of carotid atherosclerosis in 
individuals aged 65 years and older (Kawamoto et aI., 2005) and in elderly patients with 
systolic hypertension (Frost et aI., 1996). After adjusting for confounders, non-HDL 
cholesterol is also a strong predictor of CHD mortality in diabetic individuals (Liu et aI., 
2005; Schulze et aI., 2004). 
Overall, these research findings suggest that non-HDL cholesterol is a reliable 
marker for cardiovascular risk in individuals with and without disease. The theoretical 
considerations reviewed above, as well as available data on performance of non-HDL 
cholesterol in defining risk, suggest considerable utility of this measure in predicting the 
risk of CHD as well as a target in lipid-lowering therapy to reduce risk. 
2.9.2 Applications of Non-HDL Cholesterol 
Non-HDL cholesterol measurements can be used in clinical practice as a treatment 
target especially in patients with elevated TO levels since estimation of the LDL 
cholesterol is less accurate at high TO levels. The NCEP ATP III (2002) has already 
recommended using non-HDL cholesterol in patients with high TO, after the goals for 
LDL cholesterol are met. However, there are no specific goals identified for TO 
concentrations. An advantage of using non-HDL cholesterol in clinical practice is that it 
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does not limit treatment options in reducing atherogenic lipoproteins such as LDL and 
VLDL cholesterol (Packard et aI., 2004). Focusing only on elevated TG levels might 
result in a treatment that specifically lowers TG concentrations but not the other 
atherogenic lipoproteins (Packard et aI., 2004). In contrast, focusing on non-HDL 
cholesterol allows more treatment options. For example, statin therapy, which is 
recommended as the first-line therapy for most dyslipidemias, produces similar reductions 
in VLDL and LDL cholesterol, thereby also reducing atherogenic TG-rich remnants 
(Packard et aI., 2004). Further, non-HDL cholesterol was chosen over plasma apo B as a 
secondary target of therapy in patients with elevated TG because of lack of standardized 
measures for apo B and the additional expense associated with this measurement (Packard 
et aI., 2004). Another advantage of using non-HDL cholesterol is that it can be used to 
assess risk in individuals that are at increased risk of CHD due to dyslipidemia associated 
with the metabolic syndrome and diabetes (Orakzai et aI., 2009). Further, non-HDL 
cholesterol has less day-to-day variability than TG and is not affected by increased TG 
levels (Wagner et aI., 2005). Unlike TG, non-HDL cholesterol also does not require an 
overnight fast. Therefore, the use of non-HDL cholesterol may be a simple and relatively 
inexpensive indicator of CHD risk. 
2.9.3 Summary 
In summary, non-HDL cholesterol incorporates both LDL cholesterol and VLDL 
cholesterol, and it reflects the cholesterol content of all apo B containing lipoproteins. In 
individuals with elevated TG levels, non-HDL cholesterol is helpful in assessing the risk 
of CHD, since it includes the increased levels of atherogenic TG-rich remnant particles 
found in VLDL. When TG levels are elevated, VLDL levels increase and as a result, LDL 
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concentrations alone cannot define the risk associated with atherogenic lipoproteins and 
therefore, non-HDL cholesterol is considered to be a better marker for the total 
atherogenic lipoprotein levels compared to LDL cholesterol alone. Finally, overnight fast 
is not required for obtaining non-HDL cholesterol and it is readily derived from the 
routine lipoprotein profile. For these reasons non-HDL cholesterol may be a highly useful 
lipid measure for assessing risk and evaluating response in treatment of hyperlipidemia. 
2.10 Waist Circumference and Coronary Heart Disease 
Despite the continuing effort to emphasize that excessive weight raises the risk for 
CHD, the prevalence of overweight and obesity continues to increase. The National 
Health and Nutrition Examination Survey (NHANES) from 1960-1962, estimated the 
prevalence of obesity to be 13.4%. By 2000, the third NHANES estimated that 64.5% of 
U.S. adults were either overweight or obese, with the prevalence of obesity rising to 
30.5% (Lofgren et aI., 2004). Research shows that persons who are overweight or obese 
have a higher risk of developing insulin resistance, the metabolic syndrome, diabetes, 
hypertension, and CHD (Ross et aI., 2000; Mokdad et aI., 1999). Weight gain in 
adulthood is also associated with high rates of cardiovascular and metabolic risk factors. 
! In 1998, The National Heart, Lung, and Blood Institute recommended guidelines that used 
BMI and waist circumference for screening overweight and obese adults (Lofgren et al., 
2004). Waist circumference is used as a measure of abdominal fat, specifically visceral fat 
(Lofgren et aI., 2004). Since abdominal fat predicts a higher risk for CHD and type 2 
diabetes, waist circumference provides more information on risk assessment than BMI 
alone (Lofgren et aI., 2004). Research has shown relationships between cardiovascular 
risk factors and metabolic risk factors and the development and progression of CVD. For 
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example, Rexrode et al. (2001) conducted a prospective cohort study, with a nine year 
follow-up period on U.S. males. Out of the total sample of22,071, CHD event occurred in 
552 individuals. In multivariate analysis, after adjusting for age, smoking, physical 
activity, parental history of myocardial infarction, alcohol intake, and multivitamin and 
aspirin use, males in the highest waist circumference quintile (2: 103.6 cm) had a 60% 
greater risk for CHD compared to males in the lowest quintile «88.4 cm). Another study 
conducted by Balkau and colleagues (2007) recruited 168,000 primary care patients from 
63 countries across five continents. It was found that, in comparison to the lowest waist 
circumference group « 94cm in males and 80 cm in females), the age and region adjusted 
CVD odds ratios were 1.28 for males in the 94-102 cm group and 1.90 in the> 102 cm 
waist circumference group; for females, the odds ratios were 1.31 for 80-88 cm group and 
1.97 for> 88 cm waist circumference group. The corresponding odds ratios for diabetes 
were higher, 1.60 and 2.65 in males, and 1.78 and 3.94 in females. 
Another prospective cohort study was done among U.S. female registered nurses 
(Rexrode et aI., 1999). During the eight year follow-up period, 320 CHD events occurred. 
In this study, after adjusting for BMI and other cardiovascular risk factors, a waist 
circumference of 2:96.5 cm was associated with a 144% increase in CHD risk compared 
with females of waist circumference <71.1 cm. Further, a study done on Finnish males 
aged 42-60 years with a follow-up period of 10.6 years concluded that abdominal obesity 
combined with smoking increased the risk of coronary events by 5.5 times, and abdominal 
obesity combined with poor cardiorespiratory fitness increased the risk of coronary events 
by approximately five times (Lakka et aI., 2002). 
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These studies show that obesity, particularly central obesity, is an independent risk 
factor for the development of CVD. Therefore, combining non-HDL cholesterol with 
waist circumference may be a good predictor of CHD risk. 
2.11 Pathogenesis of Coronary Heart Disease 
CHD is caused by the narrowing of the coronary artery that supplies nutrients and 
oxygen to the heart. The main reason for the narrowing of the coronary artery is 
arthrosclerosis. Atherosclerosis is a chronic disease affected by both genetic, behavioural, 
and environment factors. The independent risk factors for CHD as identified by the NCEP 
A TP include age, gender, hypertension, smoking, diabetes, family history of premature 
CHD, elevated plasma levels of LDL cholesterol (2: 160 mg/dL), and low levels of HDL 
cholesterol «40 mg/dL). Hyperlipidemia is one ofthe major causes of atherosclerosis and 
associated conditions such as CHD, ischemic cerebrovascular disease, and peripheral 
vascular disease (Jain et aI., 2007). Atherosclerosis is the result of degenerative changes 
occurring in the intima layer of medium and large sized arteries (Jain et al., 2007). This 
degenerative change includes accumulation of lipids, carbohydrate molecules, blood and 
its components, and cellular waste products, along with the formation of fibrous tissues 
and calcium deposits in the intima of blood vessels (Jain et aI., 2007). These deposits or 
plaques gradually decrease the lumen of the artery, reduce its elasticity, and the plaque 
may rupture leading to the occlusion of blood vessels. 
The development of atherosclerosis is subdivided into various stages from the 
normal, healthy coronary artery to the final stage leading to its complete blockage 
resulting in myocardial infarction. The cross-sectional and the longitudinal view of the 
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coronary artery in different stages ofthe atherosclerosis process are illustrated in Figure 4. 
and described below. 
Before the onset of atherosclerosis, the coronary artery is smooth and free of any 
accumulation and deposits as seen in stage I in Figure 4. However, with increasing age, 
atherosclerotic lesions start to develop. Atherosclerotic lesions develop as a result of 
inflammation due to release of various cytokines, proliferation of smooth muscle cells, 
synthesis of connective tissue matrix, and accumulation of macrophages and lipid in the 
arterial wall (Crowther, 2005). The early stage in the development of the atherosclerotic 
plaque is the result of the changes in functions of the endothelium. Once the arterial wall 
is injured, the body's defence mechanisms respond. Macrophages invade the injured area 
and stick to the endothelial wall. Atherosclerosis may also be initiated when endothelial 
cells increase the expression of adhesion molecules such as vascular cell adhesion 
molecule-l in response to turbulent blood flow in the presence of abnormal lipid levels 
(Crowther, 2005). Stage II in Figure 4. show small amounts of lipid deposition and 
formation of fatty streaks but at this stage they do not produce any obstruction or 
symptoms. This is the beginning of the arthrosclerosis process. 
Lipids are important for the formation and development of the plaque. Three 
major atherogenic lipoproteins are deposited from the blood into the walls of the arteries. 
They include LDL, especially small dense LDL, remnant lipoproteins, and lipoprotein (a). 
These atherogenic lipoproteins, once deposited in the intima layer, are subjected to 
chemical modifications such as oxidation, thereby leading to a series of biological 
reactions (Longenbaker, 2005). Once the LDL cholesterol is deposited within the artery, 
there are three possible outcomes. The LDL may move back into the bloodstream, it may 
become oxidized through action of free radicals and activity of leukocytes, or it may be 
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taken up by monocyte or macrophages and converted to foam cells (Crowther, 2005). If 
the outcome is the latter, then macrophages bind the oxidized LDL particles to the 
receptors known as scavenger receptors. Macrophages filled with LDL are called foam 
cells. The uptake of oxidized LDL particles though the scavenger receptors reduces the 
mobility of the macrophages thereby promoting the accumulation of foam cells in the 
intima (inner layer of the artery) (Crowther, 2005). The foam cells secrete various 
cytokines and inflammatory mediators thereby promoting further recruitment and 
proliferation of smooth muscle cells, further LDL oxidation, recruitment of additional 
foam cells, and increasing the endothelial dysfunction (Crowther, 2005). A collection of 
foam cells creates a fatty streak. Enlargement of the atherosclerotic plaque is 
characterized by the accumulation of foam cells over time. As illustrated in stage III, the 
increased build-up of fatty layers in the coronary artery starts to interfere with the blood 
flow through the artery. 
Over time, slowly growing plaques gradually accumulate lipid within foam cells. 
These foam cells along with proliferation of smooth muscle cells, components of the 
intracellular matrix, and calcium ions produce the definitive fibrous plaque (Longenbaker, 
2005). In general, such plaques tend to have firm endothelial layers that are not prone to 
sudden disruption. This is seen in stage IV. However, in some cases, plaques within the 
inner lining of the coronary artery may develop a slight crack or rupture, which stimulates 
the production of the blood clots (Jain et aI., 2007). The clots also get into the crack and 
cause further obstruction of the artery, as seen in stage V. The supply of the blood flow to 
the heart muscle is substantially reduced and the patient begins to have severe and 
prolonged chest pain that occurs at rest. This is known as unstable angina (Jain et aI., 
2007). In some cases the clot does not fully close the channel of the artery and sufficient 
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blood flow is maintained in the heart muscle, and a heart attack may not develop, 
provided appropriate and prompt treatment is effected. However, the clot may continue to 
grow as large as to completely block blood flow through an artery, causing the tissue 
supplied by the artery to die. This is shown is stage in VI. 
2.12 Summary of the Literature Review 
In summary, even though it is suggested that hypertriglyceridemia is a risk factor 
for CHD, it is difficult to detennine if it can independently predict the risk of CHD 
because of its association with abnonnal lipid metabolism as well as other CHD risk 
factors. Further, it is suggested that unlike cholesterol, TG itself is not deposited in the 
atherosclerotic plaques. Instead, the effect of TG on the fonnation of atherosclerotic 
plaques can be explained by the accumulation of cholesterol-rich VLDL remnants and the 
structural abnonnalities in LDL and HDL particles caused by hypertriglyceridemia. High 
levels of TG cause increase in small dense LDL cholesterol and decrease in the size and 
quantity of HDL cholesterol, thereby reducing cardioprotective effects of HDL 
cholesterol. 
In contrast, non-HDL cholesterol has no such limitations. It includes all potential 
atherogenic lipoproteins, including LDL, IDL, and VLDL cholesterol. Non-HDL 
cholesterol is highly correlated with total apo B concentration which is the major 
apolipoprotein of all atherogenic lipoproteins. It can be used as a predictor of CHD in 
individuals with high TG levels, type 2 diabetes, and metabolic syndrome. There is less 
day-to-day variability in non-HDL cholesterol compared to TG concentrations and is 
unaffected by TG levels. Unlike TG, non-HDL cholesterol requires measurements of only 
total cholesterol and HDL cholesterol which can be measured reasonably accurately in the 
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non-fasting state. Finally, by combing all atherogenic lipoproteins into a single fraction, 
the use of non-HDL cholesterol may be a simple and relatively inexpensive indicator of 
CHD risk. 
Overall, research findings suggest that non-HDL cholesterol is a reliable marker 
for cardiovascular risk in individuals with and without elevated TO levels. Studies have 
shown that central obesity measured in waist circumference, is an independent risk factor 
for the development of CHD. The theoretical considerations reviewed above, as well as 
results from other research studies suggest the use of non-HDL cholesterol and waist 
circumference in estimating the risk of CHD. 
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CHAPTER 3. STUDY OBJECTIVE 
3.1 Purpose 
Despite some indications from research conducted that non-HDL cholesterol is a 
better predictor of CHD risk than TO, there is lack of conclusive research in this area. 
Research is needed to determine whether, and to what degree, non-HDL cholesterol is a 
better predictor of CHD risk. As identified in the literature, there is lack of information 
with respect to the combination ofnon-HDL and waist circumference and its effect on the 
risk of CHD. The purpose of this study will be to examine the relationship between non-
HDL cholesterol, waist circumference and the risk of CHD, and between 
hypertriglyceridemic waist phenotype and the risk of CHD. 
3.2 Research Question 
This study plans to address the following research question: 
Is the combination of non-HDL cholesterol and waist circumference the 
same as or better than hypertrigyceridemic waist phenotype in predicting the risk 
ofCHD? 
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CHAPTER 4. METHODOLOGY 
The Framingham Offspring Study dataset was used to compare ifusing non-HDL 
cholesterol and waist circumference is same as or better than using hypertriglyceridemic 
waist phenotype in predicting the risk of CHD. In addition, the associations between non-
HDL cholesterol, waist circumference and non-fatal CHD and between TO, waist 
circumference and non-fatal CHD were examined. This section describes the variables 
included in the analyses and the statistical procedures used to analyze the Framingham 
Offspring study data. 
4.1 Study Sample 
The public accessible dataset of the Framingham Offspring Study was obtained 
from the National Heart Lung and Blood Institute (NHLBI) after submitting the approved 
letter from the Research Ethics Board, Brock University for this secondary data analysis 
(Appendix III). The original Framingham Cohort Study began in 1948 under the U.S. 
Public Health Service. Participants were sampled from Framingham, Massachusetts. The 
Framingham Study is a longitudinal investigation of various risk factors influencing the 
development of CVD in males and females. Although the Framingham cohort is primarily 
white, the importance of the major CVD risk factors identified in this group have been 
shown in other studies to apply almost universally among racial and ethnic groups, even 
though the patterns of distribution may vary from group to group (NHLBI, 2007). 
The Framingham Offspring Study began in 1971. A new cohort consisting of the 
offspring of the original participants and each offspring's spouse were invited to 
participate in the Framingham Offspring Study. The Framingham Offspring Study was 
conducted to study the incidence and prevalence, trends, and family patterns of CVD and 
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its risk factors. The first examination took place between 1971 and 1975 which consisted 
of 5,124 males and females, ages 13 to 62 years. However, waist circumference 
measurements were not collected until the fourth examination so data from the fourth 
examination was used as the baseline. The fourth examination took place between 1987 
and 1990. At the fourth examination, the participants underwent a routine medical history, 
a physical examination that included blood pressure measurement and anthropometry, and 
blood sampling after an overnight fast. Participants had completed three examinations 
with intervals of four years and have been followed for morbidity and mortality over that 
time period. After the fourth examination, the participants were followed up for an 
average of 11 years. 
The fourth examination had 4,989 participants and after excluding those aged <40 
years old there were 3,460 individuals. Further, excluding missing information on total 
cholesterol, HDL cholesterol, TO, waist circumference, and fasting less than nine hours, 
3,196 individuals were eligible for the study, of which 1,572 were males and 1,624 were 
females. The drop in the study sample due to missing information was around 7.6%. 
Sample selection procedure is summarized in Figure 5. 
4.2 Measurement of Study Variables 
4.2.1 Follow-up and Outcome Events 
For a participant with a CHD event, the follow-up period was defined as the time 
interval from the fourth examination to the date the CHD event occurred. For a 
participant without CHD event, the follow-up time will be defined as the time interval 
from the fourth examination to the date that the individual was last known alive. The 
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amount of follow-up time was expressed in person-years for Cox proportional hazards 
models. 
All the participants were monitored for CHD occurrence through periodic 
examinations. An endpoint adjudication committee consisting of three cardiologists 
reviewed hospitalization and physician office visit records for all suspected CHD events 
(Ingelsson et aI., 2007). The diagnosis of incident CHD included MI recognized with 
diagnostic ECG, MI recognized with transaminase and history, MI recognized with 
autopsy evidence, silent and non-silent MI, angina pectoris, or acute coronary 
insufficiency. Events were considered fatal if the participant died before or during the 
hospitalization for the event, otherwise they were considered non-fatal. 
4.2.2 Waist Circumference 
Waist circumference was measured at the umbilicus while the participant was 
standing, with the tape measure parallel to the floor. In order to convert inches to 
centimetres, the waist circumference values were multiplied by 2.54. 
4.2.3 Lipid measurements 
Lipids and lipoproteins were determined on plasma samples collected after an 
overnight fast of 2:9 hours. Serum TG was measured using the semi-automated Lederer 
Kessler method (Kessler et aI., 1965). Fasting venous blood samples were collected in 
tubes containing 0.1% EDTA. Total cholesterol levels were determined by the Abell-
Kendell method (Abell et aI., 1952). Managanese-heparin precipitation method was used 
to measure HDL cholesterol. Non-HDL cholesterol was calculated by subtracting the 
HDL cholesterol from the total cholesterol. LDL cholesterol was calculated from 
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measured values of total cholesterol, TO, and HDL cholesterol according to the 
Friedewald formula: [LDL cholesterol] = [Total cholesterol]-[HDL cholesterol]-[TO/5]. 
[TO/5] is an estimate ofVLDL-cholesteroI. The calculation is valid for TO S 400 mg/dL. 
LDL-cholesterol was reported only for participants fasting for at least nine hours. All lipid 
values are expressed in mg/dL. 
Hypertriglyceridemic waist phenotype was defined as concurrently having plasma 
TO levels of ~177 mg/dL and waist circumference of ~90 cm in males (Lemieux et aI. 
2000), and plasma TO levels of ~150 mg/dL and waist circumference of ~88 em in 
females (LeMonte et aI., 2003). The criteria for non-HDL cholesterol and waist 
circumference and TO and waist circumference are listed in Table 5. 
4.2.4 Covariates 
a) Sex was coded as males=l and females=O. In the analysis, females was used as the 
reference group 
b) Age at baseline was recorded in years and used as a continuous variable. 
c) Smoking status was determined by asking the participants if they smoked 
cigarettes regularly in the past year and it was coded as yes=l and no=O. 
d) Alcohol consumption was recoded as the total alcohol consumption in ounces per 
week and used as a continuous variable. 
e) Diabetes mellitus was defined as having a fasting glucose level of~126 mg/dL. In 
the analysis, diabetes status was coded as yes=l and no=O. 
f) Systolic and diastolic blood pressure measurements (mmHg) were obtained by 
taking the average of two readings recorded by the physician at baseline 
examination. Hypertension status was determined if the participant had systolic 
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blood pressure of~140 mmHg or diastolic blood pressure of~90 mmHg or if the 
patient was receiving treatment for high blood pressure. Hypertension status was 
coded as yes= 1 and no=O. 
4.3 The receiver operating characteristic (ROC) curves 
ROC curves provide a measure of classification or prediction accuracy and are 
used to compare the discrimination ability of various diagnostic tests (Goddard et aI., 
1990; Zweig et aI., 1993). The ROC curve is a plot of sensitivity against one minus the 
specificity. Sensitivity is the proportion of true positives which are correctly identified as 
such by the diagnostic test. Specificity is the proportion of true negatives which are 
correctly identified by the test as being negative. One minus specificity, also known as 
false positive proportion is the proportion of true negatives that are falsely identified as 
positive by the diagnostic test. Sensitivity is plotted on the y-axis and one minus 
specificity is plotted on the x-axis. The area under the ROC curve (ROC AVC) is large for 
a model with high predictive accuracy. Conversely, ROC curve rises slowly and has a 
smaller area under the curve for models with low predictive accuracy (Metz, 1978). An 
ROC AVC of 0.5 represents chance prediction. If the two ROC areas under the curves are 
the same then the two tests provide equal delectability of the disease. 
4.4 Statistical analyses 
Descriptive statistics including means and proportions, stratified by gender were 
performed to get an overview of the sample at baseline. Age and gender adjusted means 
for the key study variables within the joint categories ofnon-HDL cholesterol and TG by 
waist circumference strata are reported. CHD event rates were calculated by dividing the 
number ofCHD events by the person-years of follow-up. 
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Non-parametric ROC analyses were used to calculate the ROC AVC (Cleves, 
2002). Logistic regression was used to generate the ROC curves for the predictors non-
HDL cholesterol and waist circumference, and TG and waist circumference. The ROC 
AVC were compared to see if using non-HDL cholesterol and waist circumference is 
better than using TG and waist circumference in predicting the risk of CHD. 
Cox-proportional hazards models were used to examine the association between 
non-HDL cholesterol, waist circumference and CHD, and TG, waist circumference and 
CHD. On the basis of the NCEP ATP III (2002) guidelines, the therapeutic goal for 
dyslipidemia management in subjects without CHD is a LDL cholesterol level <130 
mg/dL. For non-HDL cholesterol, the cut-points are 30 mg/dL higher than for LDL 
cholesterol to account for the VLDL cholesterol fraction. Therefore, the cut-off for non-
HDL cholesterol is ~160 mg/dL. To examine the joint distributions of non-HDL 
cholesterol and waist circumference, four groups were created: 
(1) Non-HDL ~160 mg/dL and waist circumference ~ 90 cm (males) or ~ 88 cm 
(females) 
(2) Non-HDL ~160 mg/dL and waist circumference < 90 cm (males) or < 88 em 
(females) 
(3) Non-HDL <160 mg/dL and waist circumference ~ 90 cm (males) or ~ 88 cm 
(females) 
(4) Non-HDL <160 mg/dL and waist circumference < 90 cm (males) or < 88 cm 
(females) 
Group 4 was used as the reference group. Four Cox-proportional hazards models 
were created in order to examine the association ofthe joint distributions ofnon-HDL 
cholesterol and waist circumference with non-fatal CHD. The first model adjusted for age 
and gender, the second model adjusted for smoking status and alcohol consumption, the 
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third model adjusted for diabetes and hypertension status, and the fourth model adjusted 
for all the confounders. 
Similarly, for the joint distributions of TG and waist circumference the following 
four groups were created: 
(1) TG ~ 177 mg/dL (males) or ~ 150 mg/dL (females) and waist circumference ~ 90 
cm (males) or ~ 88 cm (females) 
(2) TG ~ 177 mg/dL (males) or ~ 150 mg/dL (females) and waist circumference < 90 
cm (males) or < 88 cm (females) 
(3) TG < 177 mg/dL (males) or < 150 mg/dL (females) and waist circumference ~ 90 
cm (males) or ~ 88 cm (females) 
(4) TG < 177 mg/dL (males) or < 150 mg/dL (females) and waist circumference < 90 
cm (males) or < 88 cm (females) 
Group 4 was used as the reference group. The four Cox-proportional hazards 
models were adjusted for in the same manner as described for non-HDL cholesterol and 
waist circumference. 
For the joint distributions of non-HDL cholesterol and TG, eight groups were 
created on basis of lipid levels and strata of waist circumference: 
(1) Waist Circumference - males ~ 90 cm, females ~ 88 cm 
(1) Non-HDL ~160 mg/dL and TG ~ 177 mg/dL (males) or ~ 150 mg/dL (females) 
(2) Non-HDL ~160 mg/dL and TG < 177 mg/dL (males) or < 150 mg/dL (females) 
(3) Non-HDL <160 mg/dL and TG ~ 177 mg/dL (males) or ~ 150 mg/dL (females) 
(4) Non-HDL <160 mg/dL and TG < 177 mg/dL (males) or < 150 mg/dL (females) 
(II) Waist Circumference - males < 90 cm, females < 88 cm 
(5) Non-HDL ~160 mg/dL and TG ~ 177 mg/dL (males) or ~ 150 mg/dL (females) 
(6) Non-HDL ~160 mg/dL and TG < 177 mg/dL (males) or < 150 mg/dL (females) 
(7) Non-HDL <160 mg/dL and TG ~ 177 mg/dL (males) or ~ 150 mg/dL (females) 
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(8) Non-HDL <160 mg/dL and TG < 177 mg/dL (males) or < 150 mg/dL (females) 
Group 8 was used as the reference group to which a hazard ratio of 1.0 for CHD 
was assigned for comparison purposes. The four Cox-proportional hazards models were 
adjusted for in the same manner as described for non-HDL cholesterol and waist 
circumference. 
The proportionality assumption for the Cox-proportional hazards model was tested 
by creating an interaction term between the independent variable and the follow-up time 
and tested its p-value in SAS. If the p-value of the proportionality term was greater than 
0.05 then the assumption was considered to be met. All statistical analyses were 
performed using SAS 9.1 (SAS Institute Inc. Cary, NC), except the ROC curves and 
significance testing of ROC AUC were prepared using STATA 10.1 (StataCorp, College 
Station, Texas). 
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CHAPTER 5. STUDY RESULTS 
5.1 Characteristics of the Study Sample 
Baseline characteristics of the Framingham offspring study stratified by gender are 
shown in Table 6. Among the 3,196 participants, 1,572 (49.2%) were males and 1,624 
(50.8%) were females. The mean age at baseline was 53.9 years for males and 53.3 years 
for females. Compared to females, males were more likely to be diabetic (males vs. 
females: 6.3 vs. 3.6%; p-value: <0.0001), hypertensive (males vs. females: 44.1 vs. 
34.5%; p-value: <0.0001), and consume more alcohol (males vs. females: 4.0 vs. 1.8 
ounce/wk; p-value: <0.0001), while there was no significant difference in proportions of 
cigarette smokers (males vs. females: 23.6 vs. 25.3%; p-value: 0.2524). Means for main 
study variables, stratified by gender are reported in Table 7. Males had higher levels of 
non-HDL cholesterol, TG, LDL cholesterol, systolic blood pressure, and waist 
circumference, while females had higher levels oftotal and HDL cholesterol. 
5.2 Coronary Heart Disease Incidence 
Following the fourth examination, the average follow-up time was approximately 
9.6 years in males and 10.1 years in females. There were 11 CHD deaths in males and 
four in females during the approximately 11 years of follow-up. A total of 416 non-fatal 
CHD events (304 in males and 112 in females) occurred during the follow-up period. All 
analyses were run on non-fatal CHD events (except for ROC curves which were run on 
both fatal and non-fatal CHD) due to the small number of fatal cases. However, when 
analyses were repeated using both fatal and non-fatal cases there was no significant 
change in the results obtained. The CHD event rate was 161.6 per 10,000 person-years 
(246.8 in males and 78.0 in females). The nonfatal CHD event rate was 155.9 per 10,000 
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person-years. Univariate analysis results presented in Table 8 indicate that although the 
hazard ratios were not significant, the association between lipids and non-fatal eHD 
showed similar trends in both males and females. Since the results for males and females 
were similar, males and females were grouped together for all subsequent analyses. 
5.3 Adjusted Means for Key Study Variables within the Non-HDL Cholesterol and 
TG Groups Stratified by Waist Circumference Status 
Age and gender adjusted mean values for key study variables within the non-HDL 
cholesterol and TO risk categories by waist circumference status are presented in Table 9. 
As expected, individuals with high non-HDL cholesterol and high TO levels had elevated 
total cholesterol, non-HDL cholesterol, TO concentrations, LDL cholesterol, waist 
circumference, systolic blood pressure, and low HDL cholesterol regardless of their waist 
circumference status. Despite having low TO, individuals with elevated non-HDL 
cholesterol still had elevated LDL cholesterol in both high and normal waist 
circumference groups. The adjusted means for all the risk factors were higher (lower for 
HDL cholesterol) in the four risk categories of elevated waist circumference group 
compared to the four risk categories of normal waist circumference. 
5.4 ROC curves 
Roe curves were generated and compared usmg logistic regression and are 
presented for both non-HDL cholesterol and waist circumference, and TO and waist 
circumference in Figure 6. The ROe AUe associated with non-HDL cholesterol and 
waist circumference and TO and waist circumference are 0.6428 (95% eI: 0.6183, 
0.6673) and 0.6299 (0.6049, 0.6548) respectively. The difference in the ROe area under 
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the curves is 1.29%. The p-value testing if the difference in ROC AVCs between the two 
models is zero is 0.10. 
5.5 Kaplan-Meier Curves 
The Kaplan-Meier curve in Figure 7 shows survival rate of the four non-HDL 
cholesterol and waist circumference risk groups. The high level non-HDL cholesterol and 
high waist circumference group has the lowest survival rate, followed by the group having 
high level non-HDL cholesterol and low waist circumference. The group with low level 
non-HDL cholesterol and low waist circumference has the highest survival rate. The 
Kaplan-Meier curve in Figure 8 shows survival rate of the four TG and waist 
circumference risk groups. The high level TG and high waist circumference group has the 
lowest survival rate, followed by the group having low TG and high waist circumference. 
5.6 Cox Proportional Hazards Models 
5.6.1 Joint Distribution ofNon-HDL Cholesterol and Waist Circumference Models 
For the joint distribution of non-HDL cholesterol and waist circumference, four 
groups were created as described in the statistical analyses section for the Framingham 
Offspring Study in Chapter 4. Cox proportional hazards models were used for the 
multivariate adjustment. In this analysis, those who concurrently had non-HDL 2:160 
mg/dL and waist circumference :::::90 cm in males or non-HDL 2:160 mg/dL and waist 
circumference :::::88 em in females were considered as high risk group and the reference 
group is those who have a non-HDL <160 and waist circumference <90 cm (males) or 
<88 cm (females). Multivariate adjusted HRs for the four models are shown in Table 10. 
In comparison to the reference group, those who were in the high risk group had a 4.3 
higher risk of a non-fatal CHD (95% CI: 1.5, 11.9) after adjustment for age and gender in 
45 
the first model, a 6.9 higher risk (95% CI: 2.5, 19.0) after adjustment for the number of 
cigarettes smoked and alcohol consumption in the second model, a 5.5 (95% CI: 2.0, 
15.0) higher risk after adjustment for diabetes and hypertension in the third model. In the 
fourth model, after adjustment for all covariates used in the previous three models, those 
who were in the high risk group still have a 3.3 (95% CI: 1.2, 9.1) times higher risk of a 
non-fatal CHD in comparison to the reference group. Age, gender, diabetes and 
hypertension status were significant predictors while cigarette smoking and alcohol 
consumption remained insignificant in the final model. 
5.6.2 Joint Distribution of Triglyceride and Waist Circumference Models 
Using a similar strategy, for the joint distribution of TO and waist circumference, 
four groups were created as described in the statistical analyses section for the 
Framingham Offspring Study in Chapter 4. In this analysis, the highest risk group was 
defined as those who had TO 2:177 mg/dL and waist circumference 2:90 cm in males and 
TO 2:155 mg/dL and waist circumference 2:88 cm in females, and the reference group was 
having TO <177 mg/dL and waist circumference <90 cm in males and TO <155 mg/dL 
and waist circumference <88 cm in females. Multivariate adjusted HRs for the four 
models are shown in Table 11. In comparing to the reference group, after adjusting for 
age and gender in the first model, the HR of a non-fatal CHD for those who were in the 
high risk group is 2.5 fold higher (95% CI: 1.2, 5.2). After adjustment for regular cigarette 
smoking and alcohol consumption in the second model, there was a 3.5 (95% CI: 1.7, 7.2) 
times higher risk of a non-fatal CHD in the high risk group. After adjustment for the 
diabetes and hypertension status in the third model, those who were in the high risk group 
had 2.5 (95% CI: 1.2, 5.2) times higher risk of a non-fatal CHD. After adjusting for all the 
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covariates used in the previous three models, the risk of a non-fatal CHD in those who 
were in the high risk group is 1.8 (95% CI: 0.8, 3.7) times higher in comparison to the 
reference group. Again, age, gender, diabetes and hypertension status were found to be 
significantly associated with non-fatal CHD risk. 
5.6.3 Joint Distribution of Non-HDL Cholesterol and TG by Waist Circumference 
Levels 
To examine the impact of the joint distribution of non-HDL, TG and WC on the 
nonfatal CHD risk, a total of eight groups were created as described in the statistical 
analyses section for the Framingham Offspring Study in Chapter 4. The HRs are adjusted 
for age, gender, smoking, alcohol consumption, diabetes and hypertension status and are 
shown in Figure 9. (Table 12 includes the HRs and the 95% CIs). The results indicate that 
elevated waist circumference was a significant risk factor for non-fatal CHD regardless of 
the lipid profile. However, in individuals with high waist circumference (~90 cm in males 
or ~88 cm in females), there was an increased risk of non-fatal CHD associated with a 
high level of non-HDL cholesterol ( ~160 mg/dL) even when TG levels were normal. 
Further, there was no difference in the risk of non-fatal CHD associated with a high level 
ofTG (~177 mg/dL in males or ~150 mg/dL in females) within the two levels of non-
HDL cholesterol. In comparison to the reference group (waist circumference <90 cm 
(males) or <88 cm (females), TG <177 mg/dL (males) or <150 mg/dL (females), and non-
HDL <160 mg/dL), individuals who had high waist circumference, high TG, and high 
non-HDL cholesterol had a 2.5 (95% CI: 1.4, 4.6) times higher risk of non-fatal CHD 
event. Individuals having high waist circumference and high TG, but normal levels of 
non-HDL cholesterol, also had a 2.5 (95% CI: 1.1, 5.5) times higher risk of a non-fatal 
CHD event. While those who had high waist circumference and low TG, but high non-
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HDL, had a 2.8 (95% CI: 1.6, 5.0) times higher risk in comparison to the reference group. 
However, those having normal levels of TG and non-HDL but high waist circumference 
still had a 1.8 (95% CI: 1.0, 3.4) times higher risk of a non-fatal CHD event. 
Among individuals who did not have high waist circumference, in comparison to 
the reference group, all other groups had approximately 2 to 3 times higher risk of non-
fatal CHD although the risk in the group with high TG but low non-HDL was not 
significant. 
The results from this analysis also confirmed that traditional risk factors such as 
age, gender, diabetes and hypertension all increase the risk of developing CHD. With 
every one year increase in age, the risk of non-fatal CHD increased by 1.0 (95% CI: 1.0, 
1.1). Males had a 2.3 (95% CI: 1.6, 3.4) higher risk of non-fatal CHD in comparing to 
females. Individuals with diabetes had a 2.1 (95% CI: 1.3, 3.4) times higher risk of 
developing non-fatal CHD in comparing to non-diabetics, while individuals with 
hypertension had 1.5 (95% CI: 1.1,2.0) times higher risk of developing a non-fatal CHD 
in comparing to those without hypertension. 
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CHAPTER 6. DISCUSSION 
6.1 Comparison between the Predictive Value of Non-HDL Cholesterol, Waist 
Circumference, and TG, Waist Circumference on the Risk of CHD 
Using the Framingham Offspring Study data, this study compared the predictive 
ability of non-HDL cholesterol and waist circumference, with that of TO and waist 
circumference on risk of developing non-fatal CHD. The ROC area under the curve 
associated with non-HDL cholesterol and waist circumference was 0.6428 (95% CI: 
0.6183, 0.6673) and for TO and waist circumference was 0.6299 (0.6049, 0.6548). The 
difference in the ROC area under the curves was 1.29%. The p-value comparing the 
difference between the predictive ability of two models was 0.10. The results suggest that 
the model including non-HDL cholesterol and waist circumference may be superior at 
predicting CHD compared to the model including TO and waist circumference. Failure to 
achieve significance at the alpha error level of 0.05 may be due to low study power and 
the loss of study power because this cohort survival data were analyzed using logistic 
regression instead of the more sensitive Cox-proportional hazards regression analysis. 
Logistic regression analysis was used as opposed to Cox regression analysis because it is 
easier to generate the ROC curves and perform the statistical test comparing the ROC 
AUC (i.e. predictive ability). The ROC curves were generated for unadjusted models and 
therefore other predictor variables for CHD were excluded for two reasons. Since both 
models were prepared in the same population, there are no differences in the additional 
risk factors between the two models, so no adjustments for covariates were required to 
control for confounding. In addition, modeling TO and waist circumference and non-HDL 
cholesterol and waist circumference alone provided an absolute measure of the predictive 
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ability of the two factors under study. If adjusted for additional factors, their importance 
would be hidden. 
The results from the joint distribution of non-HDL cholesterol and TG 
concentrations confirm that elevated waist circumference increases the risk for non-fatal 
CHD event. Non-HDL cholesterol and waist circumference was highly associated with 
the risk of non-fatal CHD in both groups of TG levels. The results also confirm that 
traditional risk factors including age, male gender, diabetes, and hypertension status are 
associated with increased risk of non-fatal CHD. Further, non-HDL cholesterol is strongly 
associated with non-fatal CHD risk, in individuals with both high and low waist 
circumference levels. 
Several previous studies have examined the predictive role of non-HDL 
cholesterol level in risk assessment of CHD. A study conducted by Orakzai et al. (2009), 
analyzed the association of non-HDL cholesterol, LDL cholesterol, HDL cholesterol, and 
TG concentrations with coronary artery calcium, a marker of atherosclerosis. After 
adjusting for age, gender, race, cigarette smoking, hypertension, obesity, family history of 
premature CHD, and increasing quartiles of lipid levels, only the association ofnon-HDL 
cholesterol with coronary artery calcium scores remained statistically significant (p = 
0.002). On the other hand, no such associations existed with LDL cholesterol, HDL 
cholesterol, and TG concentrations (Orakzai et aI., 2009). In a study conducted on the 
Framingham cohort who were initially free from CHD, VLDL cholesterol predicted CHD 
risk after adjustment for LDL cholesterol (Liu et al 2006). Further, within each LDL 
cholesterol category, non-HDL cholesterol levels were predictive of CHD events but 
within each non-HDL cholesterol category, LDL cholesterol was not predictive of CHD 
events (Liu et al 2006). As expected, both LDL cholesterol and non-HDL cholesterol 
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predicted CHD events in patients with TG concentrations <200 mg/dL, however, LDL 
cholesterol was not effective in predicting CHD risk in patients with TG 2:200 mg/dL 
while non-HDL cholesterol remained predictive (Liu et al 2006). Hence, non-HDL 
cholesterol is a better predictor of CHD events and can be utilized to identify individuals 
with high risk of CHD regardless of their TG levels. Non-HDL cholesterol reflects the 
risks of both elevated TG levels and LDL cholesterol. The Lipid Research Clinics 
Program Follow-up study investigated the relationship between CHD and various 
lipoproteins over a 19 year follow-up period. It was found non-HDL cholesterol was a 
strong predictor of CHD death in both males and females, where a 30 mg/dL increase in 
non-HDL cholesterol levels results in a 19% increase in CHD death among males and 
15% among females (Cui et aI., 2001). Numerous studies have also shown that non-HDL 
cholesterol is a strong predictor of CHD deaths among individuals with diabetes (Liu et 
aI., 2005; Lu et aI., 2003) as well as among non-diabetics (AI-Daghri et aI., 2007). 
Although numerous studies have demonstrated the level of non-HDL cholesterol as an 
important predictor of the risk for CHD, based on an extensive review of the literature, 
this is the first study to have evaluated and compared the predictive value of the joint 
distribution of non-HDL cholesterol and waist circumference, and TG and waist 
circumference among individuals with CHD. 
Non-HDL cholesterol measurement has several potential advantages for clinical 
practice. In clinical lipoprotein analysis, the level of LDL cholesterol is usually estimated 
using the Friedewald's formula, based on the measurements of total and HDL cholesterol 
as well as TG concentrations, which are used to estimate the value of VLDL cholesterol. 
However, the estimate of this formula becomes progressively less accurate as TG levels 
increase, and the formula is no longer considered accurate enough for use when TG levels 
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reach 400 mg/dL. Although the Friedwald formula includes IDL cholesterol and 
lipoprotein (a) in the LDL cholesterol level measurement, they do not include remnant 
cholesterol particles. Since non-HDL cholesterol includes all the potentially atherogenic 
lipoproteins including the LDL cholesterol, IDL cholesterol, and VLDL cholesterol 
remnants, theoretically, it should be a better indicator of risk for non-fatal CHD than LDL 
cholesterol (Orakzai et aI., 2009; Liu et aI., 2006). In particular, the inclusion of VLDL 
remnants in the non-HDL cholesterol level measurements would enhance the assessment 
of CHD risk. Hence, measurements of non-HDL cholesterol levels are not limited by 
assumptions about the relationship between VLDL cholesterol and TO concentrations. In 
some individuals, especially in patients with diabetes, the relationship between VLDL 
cholesterol and TO levels may be altered, resulting in falsely low LDL cholesterol levels 
as calculated by the Friedwald formula, especially if TO levels are elevated to >400 
mg/dL (Lu et aI., 2003). In this setting, non-HDL cholesterol can be used to indicate the 
risk for CHD. Non-HDL cholesterol level may also be useful in identifying individuals 
who have the atherogenic lipoprotein phenotype found in patients with metabolic 
syndrome and diabetes mellitus and characterized by elevated TO-rich lipoproteins 
including the VLDL cholesterol and IDL cholesterol, and decreased levels of HDL 
cholesterol (Orakzai et aI., 2009). It is estimated that approximately 20% of the American 
population have this phenotype (Orakzai et aI., 2009). Further, studies that support the 
independent association of elevated TO levels and CHD emphasize the atherogenicity of 
VLDL cholesterol. Unlike cholesterol, TO itself is not deposited in the atherosclerotic 
plaques. Instead, the effect of TO on the formation of atherosclerotic plaques can be 
explained by the accumulation of TO-rich VLDL remnants and the structural 
abnormalities in LDL and HDL particles caused by high TO levels (Packard et aI., 2004). 
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A recent study conducted by Liu et al (2006), has suggested that elevated VLDL 
cholesterol is an independent predictor of CHD risk regardless of the TG levels. VLDL 
cholesterol are atherogenic because they can be taken up by macrophages, resulting in 
increased formation of foam cells and speeding up the process of atherosclerosis (Lu et 
aI., 2003). Elevated VLDL cholesterol levels are also associated with increased release of 
prothrombotic and procoagulant factors (Lu et aI., 2003). Thus, the NCEP ATP III (2002) 
recommended the use of non-HDL cholesterol as a secondary target of lipid lowering, 
after achieving adequate control ofLDL cholesterol and ifTG levels are elevated to 2:200 
mg/dL. Another benefit of using non-HDL cholesterol is that it can be calculated in the 
non-fasting state by simply subtracting the levels of HDL cholesterol from the total 
cholesterol and it is also known to have less day to day variability compared to TG levels 
(Wagner et aI., 2005). Thus, simultaneous measurement and interpretation of non-HDL 
cholesterol and waist circumference may be a simple screening tool for identifying 
individuals with non-fatal CHD. 
Abdominal obesity measured via waist circumference is also recognized as a 
major risk factor for CHD. The risk associated with increased waist circumference is due 
to the presence of visceral adipose tissue, which promotes insulin resistance, 
dyslipidaemia, and hypertension. A meta-analysis of the prospective cohort studies and 
randomized clinical trials showed that elevated waist circumference levels have strong 
significant association with the risk of CHD events and deaths (Koning et aI., 2007) 
independent of BMI and conventional CHD risk factors (Canoy, 2008). Therefore, simple 
measures of abdominal obesity such as waist circumference should also be used along 
with non-HDL cholesterol to identify individuals with high CHD risk. 
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6.2 Strengths and Limitations 
6.2.1 Strengths 
The strengths of the study are 1) The Framingham Offspring Study is a 
prospective cohort study, originally designed to examine the risk factors of CHD. 2) The 
baseline information as well as the end point (non-fatal CHD) was well documented and 
the follow-up records are reliable. 3) Waist circumference measurements were used as an 
indicator of obesity instead of BMI. 4) The study was able to control for age, gender, 
cigarette smoking, alcohol consumption, diabetes and hypertension. 
6.2.2 Limitations 
Results should be interpreted with caution. The possible limitations include: 1) 
Since the obtained Framingham Offspring Study dataset was a limited version for public 
access, some variables were blocked in order to maintain confidentiality. 2) The 
Framingham Offspring Study dataset. Since the Framingham Offspring Study only 
recruited Caucasians, the findings may not be generalizable to the other ethnic groups. For 
instance, it is known that African Americans generally have lower levels of LDL 
cholesterol in comparison to Caucasians (Cohen et aI., 2005) and yet they seem to have 
higher rates of cardiovascular mortality across all age groups (Mensah et aI., 2005). 3) 
Adding more sample size or increasing the follow-up period would enhance the study 
power. 4) Significance testing of Cox proportional hazards models using C-statistic 
difference was not corrected out (needs boot strapping). 5) Calibration was not evaluated. 
6) Diabetes status was determined by using fasting blood glucose concentration of 2:126 
mg/dL. Doctor's diagnosis of diabetes was not considered because no data was found in 
the Framingham Offspring Study dataset. 7) Other factors such as family history, physical 
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activity, diet, and socioeconomic status were not controlled for in the analyses since no 
data were available. 
6.3 Conclusion 
This is the first study to compare the predictive ability of non-HDL cholesterol, 
waist circumference and TG, waist circumference in predicting the risk of CHD. The 
results suggest that non-HDL cholesterol and waist circumference may be superior to TG 
and waist circumference in predicting the risk of CHD. The NCEP ATP III (2002) has 
recommended LDL cholesterol as the primary target of therapy. However, many 
individuals are at increased risk of CHD due to high concentrations of atherogenic 
lipoproteins not reflected in LDL cholesterol measurement, especially patients with 
dyslipidemia associated with the metabolic syndrome and diabetes. Use of non-HDL 
cholesterol as target for therapy in individuals with mild to moderate TG elevation will 
serve to improve treatment. Non-HDL cholesterol could be a simpler alternative and may 
give a more appropriate estimation of the risk of CHD. The use of non-HDL cholesterol 
and waist circumference as a primary target for cholesterol lowering therapy deserves 
further investigation. Further, substitution of non-HDL cholesterol and waist 
circumference for hypertriglyceridemic waist phenotype may help in screening 
individuals with high CHD risk so that measures can be taken to prevent the occurrence of 
CHD. 
Future research should validate the findings of this study in a larger and a diverse 
population by using a more sensitive method for comparing the predictive ability of the 
two models. Comparison should also be made between non-HDL cholesterol, waist 
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circumference and other markers of atherogenic lipoproteins such as apo B, ratio of total 
to HDL cholesterol, and HDL cholesterol. 
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APPENDIX I 
Table 1: NCEP ATP III Classification ofLDL and Non-HDL Cholesterol 
Classifi cati on 
Optimal 
Near Optimal 
Borderline High 
High 
Very High 
LDL Cholesterol Level 
(mg/dL) 
<100 
100-129 
130-159 
160-189 
~190 
Non-HDL Cholesterol Level 
(mg/dL) 
<130 
130-159 
160-189 
190-119 
~220 
(NCEP ATP 1lI, 2002) - National Cholesterol Education Program Adult Treatment PanelllI 
68 
Table 2: NCEP ATP III Classification of Serum HDL Cholesterol 
Classification HDL Cholesterol Level (mg/dL) 
Low HDL Cholesterol 
High HDL Cholesterol 
<40 
2:60 
(NCEP ATP III, 2002) - National Cholesterol Education Program Adult Treatment Panel III 
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Table 3: Clinical Identification of Metabolic Syndrome 
Risk Factor Deiming Level 
Abdominal Obesity (cm) 
Males 
Females 
High Triglyceride Level (mg/dL) 
Low HDL Cholesterol Level (mg/dL) 
Males 
Females 
Blood Pressure (mmHg) 
Fasting Glucose (mg/dL) 
>102 
>88 
~150 
<40 
<50 
~130/85 
~100 
(NCEP ATP III, 2002) - National Cholesterol Education Program Adult Treatment Panel III 
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Table 4. NCEP ATP III Classification of Triglyceride Levels 
Classification Triglyceride Level (mg/dL) 
Nonnal <150 
Borderline high 
High 
Very high 
150-199 
200-499 
>500 
(NCEP ATP III, 2002) - National Cholesterol Education Program Adult Treatment Panel III 
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Table 5: Non-HDL, Waist Circumference and High Triglyceride, Waist Circumference 
Criteria 
Gender 
Males 
Status 
High 
Low 
High 
Females 
Low 
Non-HDL Cholesterol, 
Waist Circumference 
2: 160 mg/ dL, 2: 90 em 
< 160 mg/dL, < 90 em 
2: 160 mg/dL, 2: 88 em 
< 160 mg/dL, < 88 em 
Triglyceride, 
Waist Circumference 
2: 177 mg/dL, 2: 90 em 
< 177 mg/dL, < 90 em 
2: 150 mg/dL, 2: 88 em 
< 150 mg/dL, < 88 em 
Non-HDL Cholesterol, Waist Circumference Criteria: NCEP ATP III, 2002 
Triglyceride, Waist Circumference Criteria: Lemieux et al. 2000; LeMonte et aI., 2003 
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Table 6: Characteristics of Participants by Gender at the 4th Examination (1987-1990), 
Framingham Offspring Study 
Variable Male Female P-values 
Mean (SD) Mean (SD) 
n 1,572 1,624 
Age (yrs) 53.9 (8.7) 53.3 (8.5) <0.05 
Marital Status (%) 
Single 5.0 5.4 
Married 85.3 76.6 
Widowed 2.0 7.0 
Divorced 6.5 9.4 
Separated 1.3 1.6 
Diabetes (%) 6.3 3.6 <0.0001 
Hypertension (%) 44.1 34.5 <0.0001 
Cigarette Smoking (%) 23.6 25.3 0.2524 
Total Alcohol Consumption (ounce/wk) 4.0 (5.4) 1.8 (2.8) <0.0001 
Follow-up time (yrs) 9.6 (2.8) 10.1 (2.1) <0.0001 
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Table 7: Key Study Variables of Participants by Gender at the 4th Examination (1987-
1990), Framingham Offspring Study 
Variable Male Female P-values 
Mean (SD) Mean (SD) 
n 1,572 1,624 
Age (yrs) 53.9 (8.7) 53.3 (8.5) <0.05 
Total Cholesterol (mgldL) 207.1 (36.9) 211.0 (40.5) <0.0001 
HDL Cholesterol (mgldL) 43.0 (11.6) 55.5 (15.2) <0.0001 
Non-HDL Cholesterol (mgldL) 164.1 (38.3) 155.5 (43.1) <0.0001 
Triglycerides (mgldL) 143.3 (103.3) 117.2 (105.2) <0.0001 
LDL Cholesterol (mgldL) 136.7 (33.6) 132.4 (37.1) <0.0001 
Waist Circumference (cm) 98.3 (10.3) 82.8 (13.6) <0.0001 
Systolic Blood Pressure (mmHg) 130.4 (17.5) 127.1 (19.7) <0.0001 
CHD Events (n)* 
Non-fatal (n) 304 112 
Fatal (n) 11 4 
CHD Event Rate (per 10,000 person yrs) 246.8 78.0 
*During follow-up 
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Table 8: Hazard Ratio* of Non-fatal Coronary Heart Disease Associated with Lipids and 
Waist Circumference, Framingham Offspring Study 
Variable Male Female 
HR (95% CI) HR (95% CI) 
Total Cholesterol (mgldL) 1.3 (0.9, 1.8) 1.4 (0.9,2.3) 
HDL Cholesterol (mgldL) 0.7 (0.4, 1.1) 0.9 (0.5, 1.5) 
Non-HDL Cholesterol (mgldL) 1.3 (0.9, 1.9) 1.4 (0.9,2.2) 
Triglycerides (mgldL) 1.1 (0.9, 1.5) 1.1 (0.8, 1.5) 
Waist Circumference (cm) 1.0 (0.7, 1.7) 1.4 (0.8,2.4) 
LDL Cholesterol (mgldL) 1.3 (0.9, 1.8) 1.4 (0.8,2.3) 
* Adjusted for age, smoking, alcohol, diabetes, and hypertension 
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Table 9: Adjusted means* for the Key Study Variables within the Non-HDL Cholesterol and 
Triglyceride Groups Stratified by Waist Circumference Status, Framingham Offspring Study 
Variables nHDL~160 n1IDL~160 n1IDL<160 n1IDL<160 
TG~177 or 150 TG<177 or 150 TG~177 or 150 TG<177 or 150 
(mg/dL) (mg/dL) (mg/dL) (mgldL) 
we ~ 90 or ~ 88 em 
n 416 594 135 622 
Age (yrs) 54.5 54.3 55.5 53.9 
Total Cholesterol (mg/dL) 242.4 233.9 178.6 180.9 
HDL Cholesterol (mg/dL) 38.7 47.8 37.9 49.5 
Non-HDL Cholesterol (mg/dL) 203.7 186.2 140.7 131.4 
Triglycerides (mg/dL) 282.6 112.2 232.5 90.4 
LDL Cholesterol (mg/dL) 154.0 163.6 97.2 113.2 
Waist Circumference (cm) 101.2 98.2 102.5 99.4 
Systolic BP (mmHg) 136.0 130.7 135.6 131.2 
CHDEvents 
Non-fatal (n) 83 113 26 90 
Fatal (n) 3 3 0 6 
Event Rate for CHD 275.0 245.7 257.8 188.0 
(per 10,000 person yrs) 
we < 90 or < 88 em 
n 126 399 43 861 
Age (yrs) 56.3 55.1 53.9 51.0 
Total Cholesterol (mg/dL) 248.8 238.6 184.9 182.6 
HDL Cholesterol (mg/dL) 40.7 51.7 46.7 57.6 
Non-HDL Cholesterol (mg/dL) 208.1 186.8 138.3 125.0 
Triglycerides (mg/dL) 231.7 101.0 196.2 76.5 
LDL Cholesterol (mg/dL) 164.0 166.8 99.2 109.8 
Waist Circumference (cm) 83.2 80.1 82.2 77.8 
Systolic BP (mmHg) 130.3 126.5 127.5 121.8 
CHDEvents 
Non-fatal (n) 20 43 4 37 
Fatal (n) 0 2 0 
Event Rate for CHD 209.7 131.3 94.9 48.0 
(per 10,000 person yrs) 
* Adjusted means for age and gender 
Waist circumference (WC) - Males: 90 cm; Females: 88 cm 
Triglyceride (TG) - Males: 177 mg/dL; Females: 150 mg/dL 
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Table 10: Hazard Ratios in Predicting the Risk of Non-Fatal Coronary Heart Disease Associated with the Joint Distribution of High Non-HDL Cholesterol and 
Waist Circumference, Framingham Offspring Study 
-- -_ ... _- -_ .. _---_._- ---_ .. __ ... _---
~odell ~odel2 ~odel3 ~odel4 ~odel5 
HR 95%CI HR 95%CI HR 95%CI HR 95% CI HR 95%CI 
nHDL2: 160 mg/dL & Wais12: 90 or 88 cm 4.3 (1.5,11.9) 6.9 (2.5,19.0) 5.5 (2.0,15.0) 3.3 (1.2,9.1) (n= 1010) 
nHDL2: 160 mg/dL & Waist< 90 or 88 cm 2.2 (0.7,7.5) 2.6 (0.8,8.8) 2.5 (0.7,8.1) 2.1 (0.6,6.9) 
(n= 525) 
nHDL< 160 mg/dL & Wais12: 90 or 88 cm 1.5 (0.5,4.8) 204 (0.8,7.5) 2.0 (0.6,6.1) 1.2 (004,3.8) 
(n= 757) 
nHDL< 160 mg/dL & Waist< 90 or 88 cm Referent Referent Referent Referent 
(n= 904) 
Age (yrs) 1.0 (1.0,1.1) 1.0 (1.0,1.1) 1.0 (1.0, 1.1) 
Gender 
Male 2.8 (2.0,3.8) 2.2 (1.5,3.1) 2.3 (1.6,3.3) 
Female Referent Referent Referent 
Regular Smoking 
Yes 1.1 (0.8,1.5) 1.1 (0.8,1.5) 1.3 (0.9, 1.8) 
No Referent Referent Referent 
Alcohol consumption (ounce/wk) 1.0 (1.0,1.0) 1.0 (1.0,1.0) 1.0 (1.0, 1.0) 
Diabetes 
Yes 304 (2.2,5.3) 2.2 (lA, 304) 2.1 (1.3,304) 
No Referent Referent Referent 
Hypertension 
Yes 2.2 (1.6,2.9) 1.6 (1.2,2.2) 1.5 (1.1,2.0) 
No Referent Referent Referent 
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Table 11: Hazard Ratios in Predicting the Risk of Non-fatal Coronary Heart Disease Associated with the Joint Distribution of High Triglycerides and Waist 
Circumference, Framingham Offspring Study 
-- - -
Modell Model 2 Model 3 Model 4 Model 5 
HR 95%CI HR 95%CI HR 95%CI HR 95% CI HR 95%CI 
TG~ 177 or 150 mg/dL & WC~ 90 or 88 cm 2.5 (1.2,5.2) 3.5 (1.7,7.2) 2.5 (1.2,5.2) 1.8 (0.8,3.7) 
(n = 551) 
TG~ 177 or 150 mg/dL & WC< 90 or 88 cm 1.9 (1.0,3.7) 1.9 (1.0,3.8) 1.7 (0.9,3.3) 1.7 (0.9,3.3) 
(n = 169) 
TG< 177 or 150 mg/dL & WC~ 90 or 88 cm 2.0 (1.0,4.1) 3.1 (1.6,6.3) 2.7 (1.3,5.3) 1.7 (0.8,3.4) 
(n = 1216) 
TG< 177 or 150 mg/dL & WC< 90 or 88 cm Referent Referent Referent Referent 
(n= 1260) 
Age (yrs) 1.0 (1.0,1.1) 1.0 (1.0,1.1) 1.0 (1.0,1.1) 
Gender 
Male 2.8 (2.0,3.8) 2.3 (1.6,3.2) 2.4 (1.6,3.4) 
Female Referent Referent Referent 
Regular Smoking 
Yes 1.1 (0.8,1.5) 1.1 (0.8,1.5) 1.3 (0.9,1.8) 
No Referent Referent Referent 
Alcohol consumption (ounce/wk) 1.0 (1.0,1.0) 1.0 (1.0,1.0) 1.0 (1.0,1.0) 
Diabetes 
Yes 3.4 (2.2,5.3) 2.2 (1.4,3.5) 2.1 (1.3,3.3) 
No Referent Referent Referent 
Hypertension 
Yes 2.2 (1.6,2.9) 1.7 (1.2,2.2) 1.5 (1.1,2.0) 
No Referent Referent Referent 
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Table 12: Hazard Ratio* (95% CI) Results for Figure 8, Framingham Offspring Study 
Non-HDL WC < 90 or 88 em WC 2: 90 or 88 em 
Cholesterol TG (mgldL) TG (mgldL) (mg/dL) 
N <177 or 150 N >=177 or 150 N <177 or 150 N >=177 or 150 
>=160 399 2.2 (1.6, 4.2) 126 3.l (1.4, 7.1) 594 2.8 (1.6, 5.0) 416 2.5 (1.4, 4.6) 
< 160 861 1 43 2.3 (0.7, 7.9) 622 1.8 (1.0, 3.4) 135 2.5 (1.1, 5.5) 
Note: * Adjusted for age, gender, smoking, alcohol consumption, diabetes, and hypertension 
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APPENDIX II 
TGI Cholesterol ratio; size and den.sity .of 
different lipoproteins 
• Triglyceride 
D CbolesteroL 
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Figure 1: Lipoprotein Classification (Jain, K.S., Kathiravan, M.K., Somani, R.S., Shishoo, 
c.J. (2007). The Biology and Chemistry of Hyperlipidemia. Bioorganic & Medicinal 
Chemistry, 15,4674-4699). 
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Figure 2: The Exogenous and the Endogenous Pathways of Lipid Transport (Jain, KS., 
Kathiravan, M.K, Somani, R.S. , Shishoo, c.J. (2007). The Biology and Chemistry of 
Hyperlipidemia. Bioorganic & Medicinal Chemistry, 15,4674-4699). 
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Figure 3: Model Providing Rationale for Use of Waist Circumference and Triglyceride 
Levels as Screening Tools for Metabolic Triad (Lemieux, I., Pascot, A., Couillard, C., 
Lamarche, B., Tchemof, A., Almera, N., Bergeron, J., Gaudet, D., Tremblay, G., 
Prud'homme, D., Nadeau, A., Despres, J-P. (2000). Hypertriglyceridemic Waist: A 
marker of the Atherogenic Metabolic Triad (Hyperinsulinemia; Hyperapolipoprotein B; 
Small, Dense LDL) in Men? Circulation, 102, 179-184). 
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Figure 4: Stages in the Progression of Atherosclerosis (Jain, K.S., Kathiravan, M.K., 
Somani, R.S., Shishoo, C.J. (2007). The Biology and Chemistry of Hyperlipidemia. 
Bioorganic & Medicinal Chemistry, 15,4674-4699). 
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Total N at fourth examination = 4,989 
{. 
Exclude age < 40 years: N = 3,460 
{. 
Exclude missing total cholesterol: N = 3,380 
{. 
Exclude missing HDL cholesterol: N = 3,363 
{. 
Exclude missing TO and fasting <9 hours: N = 3,212 
{. 
Exclude missing waist circumference: N = 3,196 
Figure 5: Sample Selection Procedure for the Framingham Offspring Study 
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Figure 6: Receiver Operating Characteristic Curves for Non-HDL Cholesterol and Waist 
Circumference, and Triglyceride and Waist Circumference, Framingham Offspring Study 
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Figure 7: Kaplan-Meier Curves for Non-HDL Cholesterol and Waist Circumference 
Groups, Framingham Offspring Study 
Note: nhdl_wc = 1: non-HDL cholesterol ~ 160 mg/dL and we ~ 90 or 88 cm 
nhdl_wc = 2: non-HDL cholesterol ~ 160 mg/dL and we < 90 or 88 cm 
nhdLwc = 3: non-HDL cholesterol < 160 mgldL and we ~ 90 or 88 cm 
nhdl_wc = 4: non-HDL cholesterol < 160 mg/dL and we < 90 or 88 cm 
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Figure 8: Kaplan-Meier Curves for Triglyceride and Waist Circumference Groups, 
Framingham Offspring Study 
Note: tg_we = 1: tg 2: 177 or 150 mg/dL and we 2: 90 or 88 em 
t~we = 2: tg 2: 177 or 150 mgldL and we < 90 or 88 em 
tg_we = 3: tg < 177 or 150 mg/dL and we 2: 90 or 88 em 
t!L.we = 4: tg < 177 or 150 mg/dL and we < 90 or 88 em 
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Figure 9: Risk of Non-fatal Coronary Heart Disease by Non-HDL Cholesterol, 
Triglyceride, and Waist Circumference Status, Framingham Offspring Study 
Note: Adjusted for age, gender, smoking, alcohol, diabetes, and hypertension 
88 
DATE: 
FROM: 
TO: 
FILE: 
TITLE: 
APPENDIX III 
June 3,2008 
Michelle McGinn, Chair 
Research Ethics Board (REB) 
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DivyaJoshi 
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Non-HDL, Waist Circumference vs. Triglyceride, Waist Circumference in 
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The Brock University Research Ethics Board has reviewed the above research proposal. 
DECISION: Secondary use of data accepted; however, please ensure that as the PI named 
on the data agreement, you have students sign confidentiality agreements. The 
confidentiality agreement form can be found on our website: 
https :llwww.brocku.calresearchservices/formsl ethics _ safety/H umans/GeneralStatementof 
Confidentiality.pdf 
This project has received ethics clearance for the period of June 3, 2008 to August 01, 
2008 subject to full REB ratification at the Research Ethics Board's next scheduled 
meeting. The clearance period may be extended upon request. The study may now 
proceed. 
Please note that the Research Ethics Board (REB) requires that you adhere to the protocol 
as last reviewed and cleared by the REB. The Board must provide clearance for any 
modifications before they can be implemented. If you wish to modify your research 
project, please refer to http://www.brocku.calresearchservices/forms to complete the 
appropriate form Request for Clearance of a Revision or Modification to an Ongoing 
Application. 
Adverse or unexpected events must be reported to the REB as soon as possible with an 
indication of how these events affect, in the view of the Principal Investigator, the safety 
of the participants and the continuation of the protocol. 
The Tri-Council Policy Statement requires that ongoing research be monitored. A Final 
Report is required for all projects, with the exception of undergraduate projects, upon 
completion of the project. Researchers with projects lasting more than one year are 
required to submit a Continuing Review Report annually. The Office of Research 
Services will contact you when this form Continuing Review/Final Report is required. 
89 
Please quote your REB file number on all future correspondence. 
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Brock University 
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500 Glenridge Avenue 
St. Catharines, Ontario, Canada L2S 3Al 
phone: (905)688-5550, ext. 3035 fax: (905)688-0748 
email: reb@brocku.ca 
http://www.brocku.calresearchservices/Ethics _Safety/Humans/Index. php 
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